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ABSTRACT 
 
Background: Brain tumor incidence rates increased over the past several decades 
in most developed countries, particularly in the elderly. 
Design: This is a descriptive retrospective study carried out in the period from 
January 1st 2009 to April 1st 2010. 
Settings: The study was conducted in two laboratories, the National Health 
Laboratory (NHL) and Alzahrawi Private Laboratory (Khartoum). 
Objectives: To study the histopathological pattern of brain tumors in Sudan. 
Methods: Data were collected from patient’s request forms in a predesigned 
questionnaire. All the histopathological slides of the study were retrieved and 
reviewed by the investigator with the help and supervision of experienced 
Histopathologists to confirm diagnosis, determine the histopathological types and 
classify the tumor using WHO grading system (2007).Ninety cases fulfilled the 
criteria of the questionnaire. The data were electronically processed and analyzed 
by computer using Statistical Package for Social Sciences (SPSS) software. 
Results: Revision of the cases were consistent with the previous diagnosis 
(100%).The age of patients ranged from 2 to 80 years, the commonest age group 
was from 40 to 50 years (23.1%). Male constituted (58.8%). Meningioma was the 
most common brain tumor constituting (53.3%) of all brain tumors. Astrocytoma 
came next (17.7%), pituitary adenoma (8.8%), craniopharyngioma (6.6%), 
ependymoma (4.4%), oligodendroglioma (3.3%), medulloblastoma (3.3%), 
epidermoid cyst (1.1%), and undiagnosed (1.1%).WHO grade (I) meningiorna was 
87.6% ,grade (II) 8.3%,grade (III) 4.2%.WHO grade (I) astrocytorna was (62.1%), 
grade (III) 6.2%, grade (IV) 31.2%. Regarding the histological sub types of 
meningioma, the most common sub type was transitional type (4 1%) , this was 
followed by meningothelial (35.4%), atypical (8.3%), fibrous (6.3%), 
Psarnrnomatous (4.2%) and anaplastic (4.2%).The most common histological 
subastrocytoma was pilocytic astrocytoma (62.1%),this was followed by 
glioblastorna (31.2%) and fibrilary (6.2%). Cerebral hemispheres were the most 
common anatomical sites (53.5%),this was followed by cerebellar hemispheres 
(l2.2%),pituitary gland (8.8%) olfactory groove ( 5.5%) and orbital ( 3.3%),other 
sites (13.7%). 
Conclusions: The study concluded that, the results were consistent with those 
revealed by WHO study. 
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 ﺨﺎﺼﺔ ﺍﻟﻤﺘﻘﺩﻤﺔ ﺍﻟﺒﻠﺩﺍﻥ ﻓﻲ ﺍﻷﺨﻴﺭﺓ ﺍﻟﻌﻘﻭﺩ ﺨﻼل ﺍﻟﻤﺦ ﻭﺭﻡ ﻤﻥ ﺍﻟﻤﺴﺠﻠﺔ ﺍﻟﺤﺎﻻﺕ ﻤﻌﺩل ﺍﺩﺩﺯﺍ ﻟﻘﺩ: ﺨﻠﻔﻴﺔ
  .ﺍﻟﺴﻥ ﻜﺒﺎﺭ ﻟﺩﻯ
 ﻤﻥ ﺍﻷﻭل ﻭﺤﺘﻰ ﻡ9002 ﻴﻨﺎﻴﺭ ﻤﻥ ﺍﻷﻭل ﻤﻥ ﺍﻟﻔﺘﺭﺓ ﻓﻲ ﺇﺠﺭﺍﺅﻫﺎ ﺘﻡ ﺭﺠﻌﻴﺔ، ﻭﺼﻔﻴﺔ ﺩﺭﺍﺴﺔ ﻫﺫﻩ: ﺍﻟﺘﺼﻤﻴﻡ
  .ﻡ0102 ﺃﺒﺭﻴل
 ﺍﻟﺯﻫﺭﺍﻭﻱ ﻭﻤﺨﺘﺒﺭ ﺍﻟﺼﺤﻲ ﺍﻟﻘﻭﻤﻲ ﺍﻟﻤﻌﻤل: ﻫﻤﺎ ﻟﻸﻨﺴﺠﺔ ﻤﻌﻤﻠﻴﻥ ﻓﻲ ﺍﻟﺩﺭﺍﺴﺔ ﻫﺫﻩ ﺇﺠﺭﺍﺀ ﺘﻡ: ﺍﻹﻋﺩﺍﺩﺍﺕ
  .(ﺍﻟﺨﺭﻁﻭﻡ) ﺍﻟﺨﺎﺹ
  . ﺍﻟﺴﻭﺩﺍﻥ ﻓﻲ ﺍﻟﻤﺦ ﻷﻭﺭﺍﻡ ﺍﻟﻤﺭﻀﻲ ﺍﻟﻨﺴﻴﺠﻲ ﺍﻟﻨﻤﻁ ﺩﺭﺍﺴﺔ ﺇﻟﻰ ﺘﻬﺩﻑ: ﺍﻷﻫﺩﺍﻑ
ﺘﻡ ﺇﻋﺎﺩﺓ ﻭﺍﺴﺘﻌﺭﺍﺽ ﻜل . ﺘﻡ ﺠﻤﻊ ﺍﻟﺒﻴﺎﻨﺎﺕ ﻤﻥ ﺍﺴﺘﻤﺎﺭﺓ ﺍﻟﻤﺭﻀﻰ ﻭﻭﻀﻌﻬﺎ ﻓﻲ ﺍﺴﺘﺒﻴﺎﻥ ﻤﻌﺩ ﻤﺴﺒﻘﺎﹰ: ﺍﻟﻁﺭﻴﻘﺔ
ﺘﺤﺩﻴﺩ ﻨﻭﻉ ﺘﻡ ﻤﺭﻀﻴﺔ ﺒﻤﺴﺎﻋﺩﺓ ﻭﺇﺸﺭﺍﻑ ﺃﺨﺼﺎﺌﻲ ﺃﻤﺭﺍﺽ ﺍﻟﻨﺴﻴﺞ ﻟﺘﺄﻜﻴﺩ ﺍﻟﺘﺸﺨﻴﺹ، ﻜﻤﺎ -ﺍﻟﺸﺭﺍﺌﺢ ﺍﻟﻨﺴﻴﺞ
ﺘﻡ ﺠﻤﻊ (. ﻡ7002)ﺔ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﻤﺭﺽ ﺍﻟﻨﺴﻴﺠﻲ ﻭﺘﺼﻨﻴﻑ ﺍﻷﻭﺭﺍﻡ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻨﻅﺎﻡ ﺘﺼﻨﻴﻴﻑ ﻤﻨﻅﻤ
ﺴﺘﺨﺩﻡ ﺍﻟﻜﻤﺒﻴﻭﺘﺭ ﻟﺘﺤﻠﻴل ﺍﻟﺒﻴﺎﻨﺎﺕ ﻤﻥ ﺨﻼل ﺒﺭﻨﺎﻤﺞ ﺍﹸ. ﺤﺎﻟﺔ ﻟﻌﺩﻡ ﺍﻜﺘﻤﺎل ﺒﻴﺎﻨﺎﺘﻬﺎ 02ﺤﺎﻟﺔ، ﻓﻴﻤﺎ ﺘﻡ ﺇﺒﻌﺎﺩ  011
 .ﺍﻟﺤﺯﻤﺔ ﺍﻹﺤﺼﺎﺌﻴﺔ ﻟﻠﻌﻠﻭﻡ ﺍﻻﺠﺘﻤﺎﻋﻴﺔ
ﺒﻴﻥ  ﺃﻋﻤﺎﺭ ﺍﻟﻤﺭﻀﻰ ﺘﺭﺍﻭﺡ ﻤﺎ ،%(001)ﺒﻕ ﺎﺍﻟﺤﺎﻻﺕ ﻤﺘﻭﺍﻓﻘﺔ ﻤﻊ ﺍﻟﺘﺸﺨﻴﺹ ﺍﻟﺴ ﻤﺭﺍﺠﻌﺔ ﻜﺎﻨﺕ: ﺍﻟﻨﺘﺎﺌﺞ
%. 8.85، ﺍﻟﺫﻜﻭﺭ ﻤﺜﻠﻭﺍ %(1.32) ﺴﻨﺔ 05 ﺇﻟﻰ  54ﺴﻨﺔ، ﻭﺍﻟﻔﺌﺔ ﺍﻟﻌﻤﺭﻴﺔ ﺍﻷﻜﺜﺭ ﺸﻴﻭﻋﺎﹰ  08ﺴﻨﺘﻴﻥ ﺇﻟﻰ 
 ﺃﻭﺭﺍﻡ ﺘﻠﺘﻬﺎ ﺜﻡ ﺍﻷﻭﺭﺍﻡ، ﻤﺠﻤﻭﻉ ﻤﻥ% 3.35 ﻤﺜل ﺤﻴﺙ ﺸﻴﻭﻋﺎﹰ ﺍﻷﻜﺜﺭ ﻜﺎﻥ ﺍﻟﺴﺤﺎﺌﻴﺔ ﺍﻷﻏﺸﻴﺔ ﺃﻭﺭﺍﻡ
 ﺍﻟﺒﻁﺎﻨﺔ ﻭﺭﻡ ،%(6.6) ﺍﻟﺒﻠﻌﻭﻤﻲ ﺍﻟﻘﺤﻔﻲ ﺍﻟﻭﺭﻡ ،%(8.8) ﺍﻟﻨﺨﺎﻤﻴﺔ ﺍﻟﻐﺩﺓ ﻭﺭﻡ ،%(7.71) ﺍﻟﻨﺠﻴﻤﺎﺕ
 ﺍﻟﻜﻴﺱ ﻭﺭﻡ ﻟﻜٍل،%( 3.3) ﻤﺜﻠﻭﺍ ﺍﻟﻨﺨﺎﻋﻲ ﺍﻷﺭﻭﻤﻲ ﻭﺍﻟﻭﺭﻡ ﺍﻟﺘﻐﺼﻥ ﻗﻠﻴل ﺍﻟﺩﺒﻘﻲ ﺍﻟﻭﺭﻡ ،%(4.4) ﺍﻟﻌﺼﺒﻴﺔ
 ﺘﺼﻨﻴﻑ ﺤﺴﺏ ﺍﻷﻭﻟﻰ ﺍﻟﺩﺭﺠﺔ ﻤﻥ ﺍﻟﺴﺤﺎﺌﻲ ﺍﻟﻐﺸﺎﺀ ﻭﺭﻡ. ﻟﻜٍل%( 1.1) ﻤﻌﺭﻭﻓﺔ ﺍﻟﻐﻴﺭ ﻭﺍﻷﻭﺭﺍﻡ ﺍﻟﺒﺸﺭﺍﻨﻲ،
%. 2.4 ﻜﺎﻥ ﺍﻟﺜﺎﻟﺜﺔ ﺍﻟﺩﺭﺠﺔ ﻭﻤﻥ ،%3.8 ﻜﺎﻥ ﺍﻟﺜﺎﻨﻴﺔ ﺍﻟﺩﺭﺠﺔ ﻭﻤﻥ ،%6.78 ﻤﺜل ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﺼﺤﺔ ﻤﻨﻅﻤﺔ
 ﺍﻟﺩﺭﺠﺔ ﻭﻤﻥ ،%1.26 ﻤﺜﻠﺕ ﺍﻟﻌﺎﻟﻤﻴﺔ ﺍﻟﺼﺤﺔ ﻤﻨﻅﻤﺔ ﺘﺼﻨﻴﻑ ﺤﺴﺏ ﺍﻷﻭﻟﻰ ﺍﻟﺩﺭﺠﺔ ﻤﻥ ﺍﻟﻨﺠﻴﻤﺎﺕ ﺃﻭﺭﺍﻡ
ﻓﻴﻤﺎ ﻴﺨﺹ ﺍﻷﻨﻭﺍﻉ ﺍﻟﻔﺭﻋﻴﺔ ﻷﻭﺭﺍﻡ ﺍﻟﻐﺸﺎﺀ ﺍﻟﺴﺤﺎﺌﻲ %. 2.13 ﻜﺎﻥ ﺍﻟﺜﺎﻟﺜﺔ ﺍﻟﺩﺭﺠﺔ ﻭﻤﻥ ،%2.6 ﻜﺎﻥ ﺍﻟﺜﺎﻨﻴﺔ
، %4.53ﻡ ﺘﺒﻌﺘﻬﺎ ﺃﻭﺭﺍﻡ ﻁﺒﻘﺎﺕ ﺍﻟﺨﻼﻴﺎ ﺍﻟﺴﺤﺎﺌﻴﺔ ﺤﻴﺙ ﻤﺜﻠﺕ ، ﺜ%14ﻓﺄﻜﺜﺭﻫﺎ ﺸﻴﻭﻋﺎﹰ ﻫﻭ ﺍﻟﻨﻭﻉ ﺍﻻﻨﺘﻘﺎﻟﻲ 
، %2.4، ﺍﻟﻭﺭﻡ ﺍﻟﺭﻤﻠﻲ ﻜﺎﻥ %3.6، ﻭﺭﻡ ﺍﻷﻨﺴﺠﺔ ﺍﻟﻠﻴﻔﻴﺔ ﻤﺜل %3.8ﻤﺜل ( ﻏﻴﺭ ﻨﻤﻭﺫﺠﻲ)ﺍﻟﻭﺭﻡ ﺍﻟﺸﺎﺫ 
ﺍﻟﻨﺠﻴﻤﺎﺕ ﻭﺭﻡ ﻓﻴﻤﺎ ﻴﺨﺹ ﺃﻨﻭﺍﻉ ﺍﻟﻔﺭﻋﻴﺔ ﻷﻭﺭﺍﻡ ﺍﻟﻨﺠﻴﻤﺎﺕ ﻓﺈﻥ ﺃﻜﺜﺭﻫﺎ ﺸﻴﻭﻋﺎﹰ ﻜﺎﻥ %. 2.4ﺍﻟﻭﺭﻡ ﺍﻟﻜﺸﻤﻲ 
، ﺜﻡ ﻭﺭﻡ ﺍﻟﻨﺠﻴﻤﺎﺕ ﺍﻟﻠﻴﻔﻴﺔ %2.13، ﺜﻡ ﺘﻼﻫﺎ ﺍﻟﻭﺭﻡ ﺍﻷﺭﻭﻤﻲ ﺍﻟﺩﺒﻘﻲ %1.26ﺕ ﺸﻌﺭﻴﺔ ﺍﻟﺨﻼﻴﺎ ﺤﻴﺙ ﻤﺜﻠ
، %5.51ﺜﻡ ﺘﺒﻌﻬﺎ ﻓﻭﻕ ﺍﻟﺴﺭﺠﻲ % 5.35ﺍﻟﻤﺦ ﻜﺎﻥ ﺃﻜﺜﺭ ﺍﻟﻤﻭﺍﻗﻊ ﺍﻟﺘﺸﺭﻴﺤﻴﺔ ﺤﻴﺙ ﻤﺜل %. 2.6ﺤﻴﺙ ﻤﺜل 
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INTRODUCTION 
Brain and other central nervous system (CNS) tumours include a 
variety of histopathologic subtypes, but the most common, by far, are 
gliomas. These tumors, which arise from the glial cells that surround and 
support neurons, include astrocytoma, glioblastoma, oligodendroglioma, 
oligoastrocytoma, and ependymoma.(1) 
Medulloblastoma, another neuroepithelial cancer, is relatively 
common in children but rare in adults. Brain tumourin children typically 
arise in the cerebellum, whereas brain tumour in adults are more likely to 
occur in the cerebral hemispheres.(1) In adults, older age at diagnosis of 
brain tumour is associated with higher tumor grade and poorer prognosis. 
Indeed, glioblastoma is among the most lethal of all tumours. Molecular 
studies of brain tumours reveal still greater heterogeneity of tumor types 
than is apparent based on histopathology, and efforts are underway to 
develop a molecular classification of brain tumour.(1) 
Very little is known about the etiology of brain and other CNS 
tumours. These tumours occur in association with several rare familial 
cancer syndromes, such as neurofibromatosis type 1 and Li-Fraumeni 
syndrome, but genetic predisposition related to such syndromes is 
unlikely to account for more than a few percent of brain tumours. The 
only clearly established environmental risk factor is ionizing radiation, 
particularly for exposures to therapeutic doses during childhood. Risks 
   
2 
 
related to modern diagnostic radiography probably are very small. Unlike 
ionizing radiation, there is little evidence that non-ionizing radiation from 
electric power lines, appliances, or cellular telephones causes brain or 
other CNS cancers.(1)  
Recorded brain tumour incidence rates increased over the past 
several decades in most developed countries, particularly in the elderly, 
but this is generally thought to be due more to improved diagnosis than to 
a real increase in incidence. Incidence of glioma is positively associated 
with socioeconomic status. In the United States, incidence is highest in 
Whites, intermediate for Blacks, and lowest for Asians; however, 
incidence rates for brain tumour exhibit less international variation than 
do most tumours, particularly when probable differences in completeness 
of diagnosis are taken into account. tumourof the brain and other CNS are 
more common in males than females. A possible role of steroid sex 
hormones has been hypothesized, and a recent report noted reduced risk 
of glioma associated with early age at menarche and early age at first live 
birth.(64) Several studies have indicated a reduced risk of glioma among 
persons with a history of allergies or certain infections, possibly 
indicating a role for immune factors.(65,66) A recent report noted an inverse 
association between use of nonsteroidal anti-inflammatory drugs and 
glioblastoma.(67) The blood-brain barrier is effective at keeping many 
potentially toxic agents in the bloodstream from reaching the glial cells 
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that give rise to most brain tumours. In studies with experimental 
animals,(68,69)The most potent known chemical neurocarcinogens are 
nitrosamides, such as nitrosoureas, which can cross the blood brain 
barrier. Such compounds can be formed in the stomach from nitrites and 
amides in the diet. Whether they are important carcinogens in humans is 
an unresolved issue. Experimental studies indicate that the developing 
nervous system is more susceptible to carcinogens than is the mature 
nervous system. The suggestion of a higher radiation-related brain tumour 
risk for children compared with adults is consistent with this 
observation.(1) 
 
   
4 
 
LITERATURE REVIEW 
Normal anatomy: 
The CNS consists of the cerebrum, brain stem, cerebellum and 
spinal cord. It has virtually no connective tissue and is therefore,               
a relatively soft, gel-like organ. The brain may be broadly but usefully 
divided into supra tentorial and infra tentorial components (tentorium 
cerebelli). The infra tentorial structure are collectively designated the 
posterior fossa elements (the cerebellum and most of the brain stem 
including the pons and medulla). The supra tentorial CNS consist of 
cerebrum (subdivided into frontal, parietal, temporal and occipital lobes) 
and deep nuclei of the basal ganglia, thalamus and hypothalamus. Within 
the CNS, the connective tissue is scant and essentially restricted to the 
adventitia of blood vessels. There are no resident lymphoid elements. 
Embryology:  
Neural tissues develop from embryonic ectoderm that is induced to 
differentiate by the underlying notochord. First, a neural plate forms; then 
the edges of the plate thicken, forming the neural groove. The edges of 
the groove grow toward each other and unlimitely fuse, forming the 
neural tube. This structure gives rise to the entire central nervous system, 
including neurons, glial cells, ependymal cells, and the epithelial cells of 
the choroid plexus.(2)  
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Cells lateral to the neural groove form the neural crest. These cells 
migrate and give rise to most of the peripheral nervous system, as well as 
a number of other a lot of structures. Neural crest derivatives include (1) 
chromaffin cells of the adrenal medulla (2) melanocytes of skin and 
subcutaneous tissues (3) odontoblasts (4) cells of the pia mater and the 
arachnoid; (5) sensory neurons of cranial and spinal sensory ganglia; (6) 
postganglionic neurons or sympathetic and parasympathetic ganglia; (7) 
Schwann cells of peripheral axons; and (8) satellite cells of peripheral 
ganglia.(2) 
Histology: 
The principal cells of the CNS are:(2) neurons, glial cells, cells that 
compose the meninges and blood vessels. 
1- Neurons vary considerably in structure and size throughout the 
nervous system and within a given brain region. 
Immunohistochemical markers for neurons and their processes, 
commonly used in diagnostic work include neurofilament protein, Neu 
N and synaptophysin. 
2- Glial cells are derived from neuroectoderm (macroglia) astrocytes 
,oligodendrocystes- ependyma) or from the bone marrow (Microglia). 
Glial cells have important structural and metabolic interaction with 
neurons and their dendritic and axonal processes; they also have a 
primary role in wide range of functions and reaction to injury 
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including inflammation, repair, fluid balance, and energy metabolism. 
The shape and size of the nucleus helps in the light microscopic 
distinction of one glial cell type from another as their cytoplasmic 
process are often not apparent on H and E preparations and can be 
demonstrated only with the use of metallic impregnation. 
Immunohistochemical or electron microscopic methods: astrocytes 
have round to oval nuclei with pale chromatin, found in white and gray 
matter. Star shaped appearance which is imparted by the multipolar, 
branching cytoplasmic processes that emanate from the cell body. The 
cytoplasm contain characteristic cytoplasmic intermediate filament 
protein called glial fibillary acidic protein (GFAP), this is seen by 
Immunohistochemical stain.  Astrocytes are the major cell Type 
responsible for repair and scar formation in the brain. 
• Oligodendrocytes: Have cytoplasmic process wrapped around the 
axons of neurons to form myelin. They have  round small lymphocytes 
like nuclei.(2) 
• Ependymal cells: Line the ventricular system. 
•  Microglia: Are mesoderm–derived cells that serve as fixed 
macrophages in CNS. 
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Neurons: 
Nerve cells, or neurons, are independent anatomic and functional 
units with complex morphologic characteristics.  They are responsible for 
the reception, transmission, and processing of stimuli; the triggering of 
certain cell activities; and the release of neurotransmitters and other 
signelling molecules.(2)    
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WHO Classification of Tumours of the CNS 
• Neuroepithelial Tumors 
– Astrocytic tumors 
– Oligodemdroglial tumors 
– Ependymal tumors 
– Mixed gliomas 
• Choroid plexus tumors 
• Neurologic tumors 
• Pineal parenchymal tumors 
• Embryonal tumors 
• Tumors of cranial/spinal nerves 
• Mesenchymal tumors, benign 
• Mesenchymal tumors, malignant 
• Uncertain histogenesis 
• Hemopoietic neoplasms 
• Cysts/tumor like lesions 
• Sellar tumors 
  
TUMOURS OF THE MENINGES   
• Tumours of meningothelial cells   
• Meningioma  
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Gliomas 
Astrocytomas: 
Pilocytic astrocytoma:  
Definition:  
A relatively circumscribed, slowly growing, often cystic 
astrocytoma occurring in children and young adults,It is characterised 
histologicall by a biphasic pattern with varying proportions of compacted 
bipolar cells associated with Rosenthal fibers and loose-textured 
multipolar cells associated with micro cysts and eosinophilic granular 
bodies/hyaline droplets.(3) 
ICD-O code: 9421/1 
Grading:  Pilocytic astrocytomas correspond to WHO grade1.(3) 
Incidence:  
Pilocytic astrocytomas comprise approximately 5-6% of all 
gliomas with an overall incidence of 0.37 per 100,000 persons per year. 
Pilocytic astrocytoma is the most common glioma in children, in whom 
the majority (67%) arise in cerebellum.(4) 
Age and sex distribution: 
Pilocytic astrocytoma most commonly develops, without a clear 
gender predilection, during the first two decades of life with an age-
adjusted incidence rate 0.8 per 100 000 persons per year.(5)  
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Localization:  
 Pilocytic astrocytomas arise throughout the neuraxis; however, in 
the paediatric population more tumors arise in the infratentorial 
region.(10)Preferred sites include the optic nerve (optic nerve 
glioma),optic chiasm/hypothalamus, thalamus and basal ganglia, cerebral 
hemispheres, cerebellum (cerebellar astrocytoma) and brain stem (dorsal 
exophytic brain stem glioma). In the paediatric population, the most 
common supratentorial site is the hypothalamus/optic pathways followed 
by the thalamic/basal ganglia region. Large hypothalamic, thalamic, and 
brain stem lesions may largely occupy the ventricle, their site of origin 
being difficult to define.(10) 
Clinical features: 
Signs and symptoms: 
Pilocytic astrocytomas produce focal neurological deficits or non-
localizing signs, e.g. macrocephaly, headache, endocrinopathy, or 
increased intracranial pressure due to mass effect or ventricular 
obstruction.(3) Seizures are uncommon, since the lesions infrequently 
involve cerebral cortex. Given their slow rate of growth, the clinical 
presentation of pilocytic tumours is generally that of a slowly evolving 
lesion. Pilocytic astrocytomas of the optic pathways often produce visual 
loss.  
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Proptosis may be seen with intraorbital examples. Early 
radiologically detected lesions may be unassociated with visual 
symptoms or ophthalmologic deficits. Hypothalamic/ pituitary 
dysfunction, including obesity and diabetes insipidus is often but not 
invariably apparent large hypothalamic examples. Some hypothalamic-
chiasmatic lesions of young children have been associated with 
leptomeningeal seeding and a poor outcome. It is unclear whether such 
tumours represent a distinct entity.(3)  
Pilocytic astrocytomas of the thalamus present with signs of CSF 
obstruction or neurological deficits, such as hemiparesis, due to internal 
capsule compression. Cerebellar pilocytic astrocytomas usually present in 
the first two decades of life with clumsiness, worsening headache, nausea 
and vomiting. Brain stem examples usually cause hydrocephalus or signs 
of brain stem dysfunction. In contrast to diffuse astrocytoma of the pons, 
which produces symmetric “pontine hypertrophy” pilocytic tumours of 
the brain stem are usually dorsal and exophytic just into the 
cerebellopontine angle.(3)  
Macroscopy:  
Most pilocytic astrocytomas are soft, grey and rather discrete. 
lntra-or paratumoural cyst formation is common. Chronic lesions may 
contain calcium or haemosiderin deposits. Optic nerve tumours also often 
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show collar-like involvement of the subarachnoid space. Primary diffuse 
leptomeningeal pilocytic astrocytoma is a rarity.(7) 
Histopathology:  
This astrocytic tumour of low to moderate cellularity exhibits an 
often biphasic pattern with varying proportions of compacted bipolar 
cells with Rosenthal fibers and loose-textured multipolar cells with 
microcysts and granular bodies/hyaline droplets. Rare mitosis, 
hyperchromatic and pleomorphic nuclei, glomeruloid vascular 
proliferation, infarct-like necrosis and infiltration of leptomeninges are 
compatible with the diagnosis of pilocytic astrocytoma and are not signs 
of malignancy.(3) 
Rosenthal fibers: 
These tapered corkscrew-shaped, brightly eosinophilic, hyaline 
masses are intracytoplasmic in location, a fact best seen on smear. 
Rosenthal fibers are most common in compact, piloid tissue. They appear 
bright blue on a Luxol fast blue (LFB) stain. Although helpful in 
diagnosis, their presence is not required. Lastly, Rosenthal fibers are 
neither specific to pilocytic astrocytoma nor indicative of neoplasia. 
 They are often seen in ganglioglioma and are a common finding in 
chronic reactive gliosis. Densely fibrillar, paucicellular lesions containing 
Rosenthal fibers are as likely to be reactive gliosis as pilocytic 
astrocytoma. Ultrastructurally, Rosenthal fibers lie within astrocytic 
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processes and consist of amorphous, electron-dense elements surrounded 
by intermediate (glial) filaments. Being composed of α-β crystallin, they 
lack GFAP immunoreactivity at all but their fibral rich periphery.(3)  
Vasculature:  
Pilocytic astrocytomas are highly vascular, as is evidenced by their 
contrast enhancement.(3) 
Regressive changes: 
Given the indolent nature and often slow clinical evolution of 
pilocytic astrocytomas, it is not surprising that regressive changes are 
seen. Marked hyalinized, ectatic vessels are one such feature.(3) 
Growth pattern:  
As a rule, pilocytic astrocytomas are macroscopically somewhat 
discrete. Thus, when anatomy permits, e.g. cerebellum or cerebral 
hemispheres, many can be removed in toto.(3)  
Infiltration of the meninges: 
 Involvement of the subarachnoid space is a common finding in 
pilocytic astrocytoma. It is not indicative of aggressive or malignant 
behaviour, nor does it portend subarachnoid dissemination.  
In contrast, it is a characteristic, even diagnostically helpful 
feature. Leptomeningeal invasion occurs at any tumour site, but is 
particularly common in the cerebellum and optic nerve. In optic nerve, 
more so than in the cerebellum, the Ieptomeningeal component may be 
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reticulin-rich. Another typical pattern of extraparenchymal spread is 
extension into perivascular spaces.(3)  
Distant spread and metastasis: 
 Surprisingly, otherwise typical pilocytic astrocytomas very 
occasionally seed the neuraxis, rarely even before the primary tumour is 
detected. The proliferation index in such cases varies but is usually low. 
Thus, this atypical behaviour of pilocytic astrocytoma cannot be 
predicted. The hypothalamus is the usual primary site. A related, less 
favourable lesion, the pilomyxoid astrocytoma, typically occurring in the 
hypothalamic region, more often undergoes craniospinal spread. This 
lesion is discussed below.(3)  
Malignant transformation: 
 As a group, pilocytic astrocytomas are remarkable in maintaining 
their WHO grade I status over years and even decades. As a rule, 
alterations over time are in the direction of regressive change rather than 
of anaplasia. One large study found the acquisition of atypia, particularly 
of increased cellularity, nuclear abnormalities and occasional mitoses, to 
be of no prognostic significance. 
 There have, however, been rare examples of pilocytic astrocytoma 
undergoing malignant transformation.(3) 
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Prognostic and predictive factors:                  
As a group, pilocytic astrocytomas are slowly growing masses 
which may stabilize at any point in their evolution. Rare examples even 
spontaneously regress. Stability in tumour grade and differentiation is 
typically maintained for decades.(3) 
Diffuse astrocytoma:  
Definition: 
A diffusely infiltrating astrocytoma that typically affects young 
adults and is characterized by a high degree of cellular differentiation and 
slow growth; the tumor occurs throughout the CNS but is preferentially 
located supratentorially and has an intrinsic tendency for malignant 
progression to anaplastic astrocytoma and ultimately, glioblastoma.(3)  
ICD codes:(3) 
- Diffuse astrocytoma   9400/3. 
- Fibrillary  astrocytoma    9420/3. 
- Gemistocytic astrocytoma  9411/3. 
- Protoplasmic astrocytoma  9410/3. 
Grading: 
Diffuse astrocytoma corresponds to WHO grade II. Although the 
gemistocytic variant appears to be particularly prone to progress to 
anaplastic astrocytoma and glioblastoma, the WHO Working Groups did 
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not recommend assigning it a WHO grade III as for anaplastic 
astrocytoma.(3) 
Incidence:  
Diffuse astrocytoma represents 10—15% of all astrocytic brain 
tumours, with an incidence rate of approximately 1.4 new cases/1 million 
population a year. Epidemiological data suggest that the incidence of 
astrocytoma in children has slightly increased during the past three 
decades in several Scandinavian countries and in North America.(12)   
Age and sex distribution: 
The age distribution of diffuse astrocytoma shows a peak incidence 
in young adults between ages 30 and 40. Approximately 10% occur 
below the age of 20, 60% between 20-45 years of age, and about 30% 
over 45 years of age with a mean of 34 years. There is a predominance of 
affected males (Male: Female ratio, 1.18: 1).(3)  
Localization:  
Diffuse astrocytoma may be located in any region of the CNS, but 
it most commonly develops supratentorially in the frontal and temporal 
cerebral lobes of both children and adults (one third of cases each). The 
brain stem and spinal cord are the next most frequently affected sites, 
while diffuse astrocytoma is distinctly uncommon in the cerebellum.(3)     
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Symptoms and signs:  
Seizures are a common presenting symptom, although in retrospect 
subtile abnormalities such as speech difficulties, changes in sensation, 
vision, or some motor changes may have been present earlier. With 
frontal lobe tumours, changes in behaviour or personality may be the 
presenting feature. Any such change may have been present for months 
before diagnosis, but symptoms may also be abrupt in onset.(3)  
Neuroimaging: 
On CT scans, diffuse astrocytoma most often presents as ill-
defined, homogeneous masses of low density without contrast 
enhancement. However, calcification, the cystic changes and even lower 
degrees of enhancement may be present early. MRI studies usually show 
hypodensity on T1-weighted and hyperintensity on T2-weighted images, 
with enhancement of the areas involved early in the evolution of the 
tumour. Gadolinium enhancement is uncommon in low-grade diffuse 
astrocytoma, but tends to appear during progression to anaplastic 
astrocytoma (WHO grade III).(3) 
 Macroscopy: 
Because of their infiltrative nature, these tumours usually show 
blurring of the gross anatomical boundaries. There is enlargement and 
distortion, but not destruction, of the invaded anatomical structures, e.g. 
cortex and compact myelinated pathways. Local mass lesions may be 
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present in either grey or yellow-white matter, but they have indistinct 
boundaries, and changes such as smaller or larger cysts, granular areas 
and zones of firmness or softening may be seen. Cystic change most 
commonly appears as a focal spongy area, with multiple cysts of varying 
size. Extensive microcyst morphology formation may cause a gelatinous 
appearance. Occasionally, a single large cyst filled with clear fluid may 
be present. Tumours with prominent gemistocytes sometimes have single, 
large smooth-walled cysts. Focal calcification may also be present, and a 
more diffuse grittiness may be observed. Extension into contra-lateral 
structures, particularly in the frontal lobes, is also observed.(3)  
Histopathology: 
Diffuse astrocytoma is composed of well differentiated fibrillary or 
gemistocytic neoplastic astrocytes on the background of a loosely 
structured often microcystic tumour matrix. In comparison to normal 
brain, cellularity is moderately increased and occasional nuclear atypia is 
a typical feature. Mitotic activity is generally absent, and a single mitosis 
does not yet allow the diagnosis of anaplastic astrocytoma.(3) The 
presence of necrosis or microvascular proliferation is incompatible with 
the diagnosis of diffuse astrocytoma. Phenotypically, neoplastic 
astrocytes may vary considerably with respect to their size, the 
prominence and disposition of cell processes, and the abundance of 
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cytoplasmic glial filaments. The pattern may vary markedly in different 
regions of the neoplasm. 
Histological recognition of neoplastic astrocytes using H&E 
staining on sectioned material depends mainly on nuclear characteristics. 
The normal astrocytic nucleus is oval to-elongate, but on sectioning, 
occasional round cross-sections are seen. It is typically vesicular with 
intermediate-sized masses of chromatin and often with a distinct 
nucleolus. Normal human astrocytes show no H&E stainable cytoplasm 
that is distinct from the background neuropil. Reactive astrocytes are 
defined by enlarged nuclei and the presence of stainable, defined 
cytoplasm, culminating in the gemistocyte, which has a mass of 
eosinophilic cytoplasm, often an eccentric nucleus, and a cytoplasm that 
extends in to fine processes. 
Differential diagnosis: The diffuse astrocytoma contains astrocytes 
that are increased in number and also usually in size, but are otherwise 
difficult to distinguish on an individual basis from the normal or reactive 
cells. In minor degrees of anaplasia, it is their number and, most 
commonly, the monotony of their morphology that is the most helpful in 
recognizing their neoplastic nature.  
Fibrillary astrocytoma: 
This most frequent histological variant of astrocytoma is 
predominantly composed of fibrillary neoplastic astrocytes. Nuclear  
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atypia is diagnostic criterion but mitotic activity, necrosis and 
microvascular proliferation are absent. A single mitosis does not allow 
the diagnosis of anaplastic astrocytomà. The occasional or regional 
occurrence of gemistocytic neoplastic cells is compatible with the 
diagnosis of fibrillary astrocytoma cell density is low to moderate. The 
cytoplasm is often scant and barely discernible, creating the appearance 
of naked nuclei. Nuclear atypia (i.e. enlarged, cigar-shaped, or irregular 
hyperchromatic nuclei) is a histological hallmark distinguishing tumour 
cells from normal and reactive astrocytes. Even prominent nuclear atypia 
is compatible with the diagnosis of diffuse astrocytoma WHO grade II so 
long as mitoses are very rare or absent.(13)  
Immunohistochemistry: Glial fibrillary acidic protein (GFAP) is 
consistently expressed.(3) 
Gemistocytic astrocytoma:  
This variant is astrocytoma is characterized by presence of a 
conspicuous, though variable, fraction of gemistocytic neoplastic 
astrocytes. Gemistocytes should amount to more than approximately 20% 
of all tumour cells.(14) 
Immunohistochemistry: the gemistocytic neoplastic astrocytes 
consistently express GFAP in their perikarya and cell processes.(3)  
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Protoplasmic astrocytoma:  
This rare variant is predominantly composed of neoplastic 
astrocytes showing a small cell body with a few flaccid processes with a 
low content of glial filaments and scant GFAP expression. Cellularity is 
low and mitotic activity absent. Mucoid degeneration and microcyst 
formation are common and characteristic features.(3) 
 Immunohistochemistry: GFAP imunostaining is variable and generally 
low.  
Anaplastic astrocytoma:  
Definition:  
A diffusely infiltrating, malignant astrocytoma that primarily 
affects adults, preferentially located in the cerebral hemispheres, and that 
is histologically characterized by nuclear atypia, increased cellularity and 
significant proliferative activity. The tumour may arise from diffuse 
astrocytoma WHO grade II or de novo, i.e., without evidence of a less 
malignant precursor lesion, and has an inherent tendency to undergo 
progression to glioblastoma.(3)  
ICD-O code: 9401/3. 
Grading: Anaplastic astrocytoma corresponds to WHO grade Ill.(3) 
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Localization: 
The localization of anaplastic astrocytoma corresponds to that of 
other diffuse infiltrating astrocytomas, with a preference to the cerebral 
hemisphere.(3) 
Histopathology: 
The principle histopathological features are those of a diffusely 
infiltrating astrocytoma with increased cellularity as compared to the 
grade II equivalent, distinct nuclear atypia and mitotic activity.   
Glioblastoma:  
Definition: 
The most frequent primary brain tumour and most malignant 
neoplasm with predominant astrocytic differentiation; histopathological 
feature include nuclear atypia, cellular pleomorphism, mitotic activity, 
vascular thrombosis, microvascular proliferation and necrosis.(3)  
ICD-O code:  9440/3. 
Grading: WHO grade IV.  
Age and sex distribution:   
Glioblastoma may manifest at any age, but preferentially affects 
adults, with a peak incidence at between 45 and 75 years of age.(15)  
Localization: Glioblastoma occurs most often in the subcortical white 
matter of cerebral hemisphere.(3) 
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Clinical features: 
The clinical history of the disease is usually short (less than 3 
months in more than 50% of cases.(3) 
Multifocal glioblastomas:  
Although multifocally is not unusual when defined radiologically, 
the incidence of truly multiple, independent gliomas occurring outside the 
setting of inherited neoplastic syndromes is unclear.(16) 
Primary and secondary glioblastoma:  
The terms primary and secondary glioblastoma were first used by 
Scherer in 1940 who noted “from a biological and clinical point of view, 
the secondary glioblastomas developing in astrocytomas must be 
distinguished from “primary” glioblastomas; they are probably 
responsible for most of the glioblastomas of long clinical duration”. The 
majority of glioblastomas (>90%) develop very rapidly with a short 
clinical history (usually <3 months), without clinical or histological 
evidence of a pre-existing, less malignant precursor lesion (primary or de 
novo glioblastoma). They typically develop in older patients (mean, 62 
years).(4,17)   
Histopathology: 
Glioblastoma is anaplastic, cellular glioma composed of poorly 
differentiated, often pleomorphic astrocytic tumour cells with marked 
nuclear atypia and brisk mitotic activity. Prominent microvascular 
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proliferation and/or necrosis are essential diagnostic features. As the term 
glioblastoma “multiforme” suggests, the histopathology of the tumour is 
extremely variable.(18) 
Tissue patterns: 
The diagnosis of glioblastoma is typically based on the tissue 
pattern rather than on the identification of certain cell types. The presence 
of highly anaplastic glial cells, mitotic activity and vascular proliferation 
and/or necrosis is required.(3) 
Epithelial structure: 
Occasionally, glioblastoma contains foci with glandular and 
ribbon-like epithelial structures. These elements have a large oval 
nucleus, prominent nucleus, prominent nucleolus and round, well-defined 
cytoplasms. They are also referred to as “adenoid” glioblastoma.(19) 
Small cell glioblastoma: although small cells are common in 
glioblastoma, they are predominant or exclusive in a subset known as 
“small cell glioblastoma.(3) 
Glioblastoma with oligodendroglioma component: Occasional 
glioblastomas contain foci that resemble oligodendroglioma.  
Multinucleated giant cells: Large, multinucleated tumour cells are 
often considered a hallmark of glioblastomas and occur with a spectrum 
of increasing size and pleomorphism.(21) 
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• Gemistocytes: At the other extreme of glioblastoma differentiation are 
“gemistocytes” and the related “fibrillary astrocyte”, recognizing that 
transition forms connect these two types.(3) 
• Granular cells: Large cells with a granular, periodic acid-Schiff (PAS) 
positive cytoplasm may occur scattered within glioblastoma. 
• Lipidized cells: Cells with a foamy cytoplasm are another feature 
occasionally observed in glioblastoma.(19) 
•  Perivascular lymphocytes: Perivascular lymphocyte cuffing occurs in 
a minority of glioblastomas. The inflammatory cells have been 
phenotypically characterized on the basis of their immunoreactivity.   
• Metaplasia: Adenoid and squamous epithelial metaplasia are more 
common in gliosarcoma than in the ordinary glioblastoma.(23) 
• Microvascular proliferation: In addition to necrosis, the presence of 
microvascular proliferation (previously called endothelial cell 
proliferation) is a histopathological hallmark of glioblastoma. On light 
microscopy classic microvascular proliferations typically appear as 
“glomeruloid tufts”.(3)`   
•  Proliferation: Proliferative activity is usually prominent. Atypical 
mitoses are frequently present.(3) 
• Angiogenesis: Glioblastomas are among the most vascularized tumours 
in humans.(24) 
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• Necrosis: Tumour necrosis is a fundamental feature of glioblastoma. 
Necrosis can be seen by neuroimaging as a non-enhancing core.(3) 
Giant cell glioblastoma: 
Definition:  
A histological variant of glioblastoma with a predominance of 
bizarre, multinucleated giant cells, an occasionally abundant stromal 
reticulin network and a high frequency of TP53 mutations.(3) 
ICD-O code: 9441/3.(3) 
Grading: Giant cell glioblastoma corresponds histologically to WHO 
grade IV.(3) 
Incidence: 
Giant cell glioblastoma is a rare variant that accounts for less than 
1% of all brain tumours and up to 5% of glioblastoma.(25) 
Age and sex distribution: 
In a series of 55 cases, the mean age at clinical manifestation was 
41 years. Males and females are equally affected (M/F ratio 1: 1).  
Clinical features: 
Symptoms and signs: 
Symptoms are similar to those of the ordinary glioblastoma.(3) 
Neuroimaging: 
Giant cell glioblastomas are distinctive because of their 
circumscription and firmness caused by the marked production of tumour 
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stroma. They are often located subcortically in the temporal and parietal 
lobes. On CT and MTI, they may mimic a mtastasis.(3)   
Oligodendroglial tumours: 
Oligodendroglioma: 
Definition: A diffusely infiltrating, well-differentiated glioma of 
adults, typically located in the cerebral hemispheres, composed of 
neoplastic cells morphologically resembling oligodendroglia and often 
harbouring deletions of chromosomal arms 1p and 19q.(3)  
ICD-O code: 9450/3.(3) 
Grading: 
Oligodendroglioma corresponds histologically to WHO grade II.(3) 
Incidence: 
Oligodendroglioma accounts for approximately 2.5% of all 
primary brain tumours and 5-6% of all gliomas.(4,5) 
Age and sex distribution: 
The majority of oligodendroglioma arise in adults, with a peak 
incidence between 40 and 45 years of age. Oligodendroglioma is rare in 
children accounting for only 2% of all brain tumours in patients younger 
than 14 years. Males affected slightly more than females, with ratio of 
(1.1 : 1).(5) 
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Localization: 
Oligodendroglioma arise preferentially in the cortex and white 
matter of the cerebral hemispheres. The frontal lobe is involved in  50-
65% of the patients followed with decreasing frequencies the temporal, 
parietal and occipital lobes. Patients have been reported with 
oligodendroglioma in the posterior fossa, basal ganglia, brain stem or 
spinal cord as well as primary leptomeningeal oligodendroglioma and 
oligodendroglia gliomatosis cerebri.(34) 
Clinical features: 
Symptoms and signs:  
Approximately two third of the patients present with seizures. 
Further common presentations include headache and other signs of 
increased intracranial pressure..(3)   
Neuroimaging:  
On CT oligodendroglioma usually appears as hypo-or isodense, 
well demarcated mass lesions.(3)   
Macroscopy: 
Oligodendroglioma usually appears as well defined soft masses of 
grayish-pink colour. 
Histopathology: 
Oligodendroglioma are diffusely infiltrating gliomas of moderate 
cellularity that are composed of monomorphic cells with uniform round 
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nuclei and perinuclear halos on paraffin sections (honeycomb 
appearance). Additional features include microcalcifications, 
mucoid/cystic degenerationand adense network of branching capillaries.(3) 
Immunohistochemistry: 
There is no immunohistochemical marker available that allows the 
specific and sensitive recognition of human oligodendroglioma tumour 
cells.(35) 
Genetic susceptibility: 
Occasionally familial clustering of oligodendroglioma has been 
reported, example, include two brothers, mother and daughter, twin 
sisters and a father and son.(3) 
Genetic:  
The vast majority showed normal or non-clonal karyotypes.(36)                                                    
Anaplastic oligodendroglioma: 
Definition: 
An oligodendroglioma with focal or diffuse histological features of 
malignancy and a less favourable features of malignancy and a less 
favourable prognosis.(3) 
ICD-O code:  9451/3.(3) 
Grading: 
 Anaplastic oligodendroglioma corresponds histologically to WHO 
grade III. Anaplastic features that have been linked to malignancy in 
   
30 
 
oligodendroglioma are high cellularity, marked cytological atypia, high 
mitotic activity, microvascular proliferation and necrosis with or without 
pseudopalisading.  
Incidence:  
Anaplastic oligodendroglioma accounted for approximately 1.2% 
of primary brain tumours and adjusted annual incidence rates ranging 
from 0.07 to 0.18 per 100,000 population have been reported.(5,4) 
Age and sex distribution: 
Anaplastic oligodendroglioma manifests preferentially in adults, 
with a peak incidence between 45 and 50 years of age.(5,4)  Anaplastic 
oligodendroglioma shows a slight male predominance, with a male  : 
female ratio of 1.1 : 1 reported in a population-based series of 781 
patients.(3)   
Localization: 
Anaplastic oligodendroglioma shares with WHO grade II 
oligodendroglioma a preference for the frontal lobe, followed by the 
temporal lobe.(3) 
Clinical features: 
Anaplastic oligodendroglioma may develop either due to novo or 
by progression from a pre-existing WHO grade II oligodendroglioma. 
The preoperative history of patients with de novo tumours is usually short 
with seizures being the most common presenting symptom.(3) 
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Neuroimaging  
Anaplastic oligodendroglioma may show heterogeneous 
patterns,owing to the variable presence of necrosis, cystic degeneration, 
intratumoural hemorrhages and calcification. Contrast enhancement on 
CTand MRI is usual and may be patchy or homogeneous. Ring-
enhancement is uncommon and when present, heralds a poor 
prognosis.(37) 
Macroscopy: 
The macroscopic features are similar to those of WHO grade II 
oligodendroglioma expect that anaplastic oligodendroglioma may 
demonstrate areas of tumour necrosis.(3)  
Histopathology: 
Anaplastic oligodendroglioma is a cellular, diffusely infiltrating 
glioma that may show considerable morphological variation. The 
majority of tumour cells demonstrate features that are reminiscent of 
oligodendroglial cells, i.e. rounded hyperchromatic nuclei, perinuclear 
halos, and few cellular processes. Focal microcalcifications are often 
present. Mitotic activity is usually prominent. Occasional tumours are 
characterized by marked cellular pleomorphism with multinucleated giant 
cells or have a conspicuous spindle-cell appearance.(3) 
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Genetics: 
Chromosomal and array-based comparative genomic hybridization 
studies have revealed total losses of 1 p and 19q in up to two thirds of 
anaplastic oligodendrogliomas, which is slightly less common than in 
WHO grade II oligodendroglioma.3) 
Ependymal tumours:  
Subependymoma: 
• Definition: A slowly growing, benign neoplasm, typically attached to a 
ventricular wall, compared of glial tumour cell clusters embedded in an 
abundant fibrillary matrix with frequent microcystic change.(3) 
•  ICD-O code: 9383/1.(3)  
•  Grading: Subependymoma corresponds histologically to WHO 
gradeI.(3) 
• Incidence: The true incidence of subependymoma is difficult to 
determine, because these tumours frequently remain asymptomatic and 
are often found incidentally at autopsy. In two studies, they accounted 
for approximately 8% of ependymal tumours.(41) 
•  Age and sex distribution: Subependymoma develop in both sexes and 
in all age groups, but occur most frequently in middle-aged and elderly 
patients.(3) 
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•  Localization: The most frequent site is the fourth ventricle, followed 
by the lateral ventricles.(3) 
•  Clinical features:  
- Symptoms and signs: Subependymoma may become clinically 
apparent through ventricular obstruction and raised intracranial 
pressure.(3) 
- Neuroimaging: subependymoma are sharply demarcated, nodular 
masses that are usually non-enhancing. Calcification and foci of 
haemorrhage may be apparent.(42) 
- Macroscopy: These tumours present as firm nodules of variable size, 
bulging into the ventricular lumen in most instances, the diameter does 
not exceed 1-2 cm.(3)  
Myxopapillary ependymoma: 
• Definition: A slowly growing,  ependymal glioma with preferential 
manifestation in young adults and almost exclusive location in the 
region of conus medullaris, cauda equina and filum terminale of the 
spinal cord, typically characterized histologically by tumour cells 
arranged in a papillary manner around vascularized myxoid stromal 
cores.(3) 
 
 
 
   
34 
 
•  ICD-O code: 9394/1.(3)  
•  Grading: These slowly growing tumours have a favourable prognosis 
and corresponds to WHO grade I. Anaplastic variants are virtually 
unknown.(3) 
• Incidence: Among all ependymomas, the frequency of myxopapillary 
variants is 9-13%.(41) 
•  Age and sex distribution: An average age at manifestation of 36 years 
has been reported with abroad range between 6 and 82 years. Male to 
female ratio was 2.2 : 1.(3) 
•  Localization: Myxopapillary ependymomas occurs almost exclusively 
in the conus medullaris-cauda equine-filum terminale region. It can be 
observed at other locations such as the cervical-thoracic, spinal cord, the 
fourth ventricle, the lateral ventricle or the brain parenchyma.(3) 
• Histopathology: Myxopapillary ependymomas are characterized by 
GFAP-expressing, cuboidal to elongated tumour cells radially arranged 
in a papillary manner around vascularized stromal cores. Some tumours, 
however, show minimal or no papillary areas and instead feature 
fascicles of more elongated cells.(3)   
• Immunohistochemistry: for GFAP, S-100 and vimentin are positive.(3) 
Ependymoma: 
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• Definition: A generally slowly growing tumour of children and young 
adults, originating from the wall of the ventricles of from the spinal 
canal and composed of neoplastic ependymal cells.(3) 
•  ICD-O code:(3) 
- Ependymoma           9391/3 
- Cellular ependymoma  9391/3 
- papillary ependymoma  9393/3 
- Clear cell ependymoma  9391/3 
-Tanycytic ependymoma  9391/3 
• Grading:  
Ependymoma corresponds histologically to WHO grade II.(3)  
• Incidence: In the United States, WHO grade II –III ependymomas have 
an approximate incidence of 0.29 in males and 0.22 per 1000, 000 
persons per year in females.(5) 
•  Age and sex distribution:  Ependymomas develop in all age groups 
with a range from 1 month to 81 years, but incidence is greately 
affected by histological type and location. Intratentorial ependymomas 
predominate in children, with a mean age at clinical manifestation of 6.4 
years and a range of 2 month to 16 years. A second age peak at 30 – 40 
years has been reported for spinal tumours. Supratentorial 
ependymomas affect paediatric as well as adult patients.  
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• Etiology: The identification of SV40 virus large T antigen-related DNA 
sequences in a significant proportion of human choroid plexus 
papillomas and ependymomas received attention since it was thought 
possible to reflect latent infection, following widespread use of SV40-
contaminated polio vaccines during 1955 -1962.  
•  Localization: These tumours may occur at any site along the 
ventricular system and in the spinal canal. They most commonly 
develop in the 4th ventricles and in the spinal cord, following by the 
lateral ventricles and the third ventricle in adults. Rare extraneural 
ependymomas have been observed in the ovaries.(41) 
• Macroscopy: Ependymoma are typically soft tan masses with well-
demarcated borders visible foci of haemorrhage or necrosis are 
uncommon.(3) 
• Histopathology: The most common or classic, pattern of ependymoma 
is a well-delineated, moderately cellular glioma with a monomorphic, 
nuclear morphology, characterized by round to oval nuclei with “salt 
and pepper” speckling of the chromatin. Mitoses are rare or absent. 
Apart from the nuclear aspects, key histological features are 
perivascular pseudorosettes and ependymal rosettes. perivascular 
pseudorosettes originate from tumour cells arranged radially around 
blood vessels with perivascular anuclear zones of gilal fibrillary protein 
(GFAP)-rich fibrillary processes.(3)   
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• Cellular ependymoma: this variant is more common extraventricular 
locations and shows conspicuous cellularity without a significant 
increases in mitotic rate.(3) 
• Papillary ependymoma: Ependymomas form linear, epithelial-like 
surfaces along their CSF exposures.(3) 
• Clear cell ependymoma: Clear cell ependymomas display an 
oligodendroglia-like appearance with clear perinuclear halos. This 
variant appears to be preferentially located in the supratentorial 
compartment of young patients.(3) 
•  Tanycytic ependymoma: Tanycytic tumours are most commonly, 
found in the spinal cord.It is para ventricular,with  elongated  
cytoplasmic processes that extend to ependymal surface. 
• Other pattern: Rare ependymoma variants include ependymoma with 
lipomatous differentiation, giant cell ependymoma, ependymoma with 
extensive tumour cell vacuotation, melanotic ependymoma, signet ring 
cell ependymoma, ovarian ependymoma, ependymoma with neuropil-
like islands and ganglioglioma with a tanycytic glial component.(3) 
Immunohistochemistry: The great majority of ependymomas display 
GFAP immunoreactivity with a prominent reaction for GFAP usually 
observed in pseudorosettes.  
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Anaplastic ependymoma: 
• Definition: malignant glioma of  ependymal differentiation with 
accelerated growth and unfavourable clinical outcome, particularly in 
children, histologically characterized by high mitotic activity, often 
accompanied by microvascular proliferation and pseudopalisading 
necrosis.(3) 
•  ICD-O code: 9392/3.(3) 
• Grading: Anaplastic ependymoma corresponds histologically to WHO 
grade III.(3)  
• Incidence: Incidence data vary considerably due to the uncertainly 
regarding histological criteria of malignancy. Anaplastic changes are far 
more frequent in childhood intracranial ependymomas, particularly 
posterior fossa examples, than in those of the spinal cord.(5) 
• Clinical features:   Signs and symptoms of anaplastic ependymomas 
are similar to those of ependymoma WHO grade II. 
• Histopathology: Anaplastic ependymoma show increased cellularity 
and brisk mitotic activity, often associated with microvascular 
proliferation and pseudopalisading necrosis. 
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Embryonal tumours: 
1- Medulloblastoma: 
• Definition: A malignant, invasive embryonal tumour of the cerebellum 
with preferential manifestation in children, predominantly neuronal 
differentiation, and an inherent tendency to metastasize via CSF 
pathways.(3) 
• ICD-O code:(3) 
- Medulloblastoma      9470/3.    
- Desmoplastic/nodular medulloblastoma   9471/3.  
- Medulloblastoma with extensive nodularity   9471/3.  
- Anaplastic medulloblastoma     9474/3.  
- Large cell medulloblastoma     9474/3.  
• Grading: Medulloblastomas correspond histologically to WHO grades 
IV.(3) 
• Age and sex distribution: The peak age at presentation is 7 years. 
Approximately 65% of patients are males.(3) 
• Etiology: Different polyomaviruses have been discussed as possible 
causative agents.(3) 
• Localization: At least 75% of childhood medulloblastomas arise in the 
vermis, and project into the fourth ventricle. Involvement of cerebellar 
hemispheres increases with the age of the patient.(3) 
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• Histolopathology: Medulloblastoma is composed of densely packed 
cells with round-to-oval or carrot shaped hyperchromatic nuclei 
surrounded by scanty cytoplasm. Neuroblastic (Homer Wright) rosettes, 
which are observed in less than 40% of cases, are often associated with 
marked nuclear pleomorphism and high mitotic activity.(3) 
• Desmoplastic/nodular medulloblastoma: This variant is characterized 
by nodular, reticulin-free zones (pale islands) surrounded by densely 
packed, highly proliferative cells with hyperchromatic and moderately 
pleomorphic nuclei which produce a dense intercellular reticulin fiber 
network.(50) 
• Medulloblastoma with extensive nodularity: The medulloblastoma 
with extensive nodularity, which was previously designated “cerebellar 
neuroblstoma” occurs in infants and differs from the related 
desmoplastic/nodular variant by having an expanded lobular 
architecture.(51)  
• Anaplastic medulloblastoma: Marked nuclear pleomorphism, nuclear 
moulding, cell-cell wrapping and high mitotic activity, often with 
atypical forms, are characteristics of this variant.(52) 
•  Large cell medulloblastoma: The large cell variant represents 
approximately 2-4% of medulloblastomas. The term derives from its 
monomorphic cells with large, round vesicular nuclei, prominent 
nucleoli and variable amount of eosinophilic cytoplasm.(3) 
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Myogenic differentiation: 
• Synonym: medullomyoblastoma (ICD-O: 9472/3): Medulloblastoma 
with myogenic differentiation was previously termed 
medullomyoblastoma. However, genetic changes in medulloblastoma 
with myogenic differentiation are similar to those in other 
medulloblastomas, this is not adistinct entity.(3) 
Melanotic differentiation:       
• Synonym: Melanocytic medulloblastoma (ICD-O: 9470/3): 
Medulloblastoma with melanotic differentiation was previously termed 
melanocytic medulloblastoma. However, groups of melanotic tumour 
cells can occur in different variants of medullobatoma and the therefore, 
this is not regarded as a separate variant.(3) 
• Immunohistochemistry: The frequent differentiation of the 
medulloblastoma along neuronal lineage manifests 
immunophenotypically as expression of neuronal antigens. Class III β-
tubulin, microtubule-associated protein 2, neuron specific enolase 
(NSE) and synaptophysin.(3) 
Central nervous system primitive neuroectodermal tumours: 
• Definition: A heterogeneous group of tumours occurring predominantly 
in children and adolescents. They may arise in the cerebral hemispheres, 
brain stem, spinal cord and are composed of undifferentiated or poorly 
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differentiated neuroepithelial cells which may display divergent 
differentiation along neuronal, astrocytic and ependymal lines. 
CNS/supratentorial PNET is an embryonal tumour composed of 
undifferentiated or poorly differentiated neuroepithelial cells. Tumours 
with only neuronal differentiation are termed cerebral neuroblastomas 
or, if ganglion cells are also present, cerebral ganglioneuroblastomas. 
Tumours that recreate features of neural tube formation are termed 
medulloepitheliomas. Tumours with ependymoblastic rosettes are 
termed ependymoblastomas. Features common to all CNS PNET 
variants include early onset and aggressive clinical behavious.(3)  
•  ICD-O codes: (3) 
- CNS PNET, NOS  9473/3.  
- CNS Neuroblastoma  9500/3.  
- CNS ganglioneuroblastoma 9490/3.  
- Medulloepithelioma  9501/3.  
- Ependymoblastoma  9392/3.  
• Grading: As with other embryonal brain tumours all CNS PNETs 
correspond histologically to WHO grades IV.(3) 
Medulloepithelioma: 
• Definition:  a rare, malignant embryonal brain tumour affecting young 
children, histologically characterized by papillary, tubular or trabecular 
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arrangements of neoplastic neuroepithelium mimicking the embryonic 
neural tube.(3)  
•  Age and sex distribution:  Medulloepitheliomas are rare tumours that 
typically affect children between 6 months and 5 years, with half 
occurring during the first two years.(53) 
• Localization: Medulloepitheliomas develop in both the supra-and 
infratentorial compartments.(53) 
• Histopathology: Medulloepitheliomas are malignant neoplasma that 
mimic the embryonic neural tube and are characterized by papillary, 
tubular or trabecular arrangements of neoplastic neuroepithelium with 
an external limiting membrane. These tumours often display multiple 
lines of differentiation, including neural glial and mesenchymal 
elements.(54) 
Ependymoblastoma: 
• Definition:  a rare, malignant embryonal brain tumour manifesting in 
neonates and young children, histologically characterized by distinctive 
multilayered rosettes.(3)  
• Age and sex distribution: consistent with the primitive neuroepithelial 
nature of the tumour, the ependymoblastoma occurs in young children, 
including neonates.(55) 
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Atypical teratoid/rhabdoid tumour: 
• Definition: A highly malignant CNS tumour predominantly manifesting 
in young children, typically containing rhabdoid cells, often with 
primitive neuroectodermal cells and with divergent differentiation along 
epithelial, mesenchymal, neuronal or glial lines, associated with 
inactivation of the IN1/hSNF5 gene in virtually all cases.(3)  
• ICD-O code:  9508/3.(3) 
• Grading: This tumour corresponds to WHO grade IV.(3) 
Tumours of the cranial and paraspinal nerves: 
• Definition: A benign nerve sheath tumour that is typically encapsulated 
and composed entirely of well-differentiated Schwann cells. Multiple 
schwannomas are associated with neurofibromatosis type 2 or 
schwannomatosis.(3)  
•  CD-O code:  9560/0. 
•  Grading: Conventional, non-melanotic schwannoma corresponds 
histologically to WHO grade I.(3)  
• Synonyms: Neurilemoma and neurinoma.(3)  
• Incidence: Schwannomas represent 8% of intracranial tumours.(56) 
•  Age and sex distribution: All ages are affected but paediatric cases are 
rare. The peak incidence is in the fourth to sixth decade of life. Most 
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studies show no gender predilection, but some series have shown a 
female.(56)  
• Localization: Intracranial schwannomas show a strong predilection for 
the eighth cranial nerve in the cerebellopontine angle.(3)  
Neurofibroma: 
•  Definition: A well-demarcated intraneural or diffusely infiltrative 
extraneural tumour consisting of a mixture of cell types, including 
Schwann cells, perineurial-like cells, and fibroblasts; multiple and 
plexiform neurofibromas are typically associated with 
neurofibromatosis type 1.(3) 
• ICD-O codes: (3) 
- Neuiofibroma   9540/0. 
-  Plexiform neurofibroma 9550/0.  
• Grading: Neurofibroma corresponds histologically to WHO grade I.(3) 
•  Incidence: Neurofibromas are common and occur either as sporadic 
solitary nodules unrelated to any apparent syndrome or, far less 
frequently, as solitary, multiple or numerous lesions in individuals with 
neurofibromatosis type 1 (NFl). 
•  Age and sex distribution: All ages and both sexes are affected.(3) 
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Meningiomas: 
• Definition: MeningotheliaI (arachnoidal) cell neoplasm, typically 
attached to the inner surface of the dura mater.(3) 
•   ICD-O code: Meningioma 9530/0.(3)  
• Grading: Most meningiomas are benign and correspond to WHO grade 
I. Certain histological subtypes or meningiomas with specific 
compinations of morphologic parameters are associated with less 
favoureble clinical outcomes and correspond to WHO grades II 
(atypical) and Ill (anaplastic or malignant).(3)  
•   Incidence: Meningiomas account for about 24—30% of primary 
intracranial tumours occurring in the USA. Meningiomas are often 
multiple in patients with neurofibromatosis type 2 (NF2).(5) 
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Meningiomas grouped by likelihood of recurrence and grade  
Meningiomas with low risk of recurrence and aggressive growth  
Meningothelial meningioma  WHO grade I 9531/0 
 Fibrous (fibroblastic) meningioma WHO grade I 9532/0 
 Transitional (mixed) meningioma  WHO grade I 9537/0 
Psammomatous meningioma   WHO grade I 9533/0 
Angiomatous meningioma  WHO grade I 9534/0 
Microcystic meningioma  WHO grade I 9530/0 
Secretory meningioma  WHO grade I 9530/0 
 Lymphoplasmacyte-rich meningioma  WHO grade I 9530/0 
Metaplastic meningioma   WHO grade I 9530/0 
Meningiomas with greater likelihood of recurrence and/or aggressive behavior
Chordoid meningioma   WHO grade II 9538/1 
Clear cell meningioma (intracranial)   WHO grade II 9538/1 
Atypical meningioma   WHO grade II 9539/1 
Papillary meningioma  WHO grade III 9538/3 
Rhabdoid meningioma WHO grade III 9538/3 
Anaplastic (malignant) merningioma  WHO grade III 9530/3 
 
• Age and sex distribution: Meningiomas occur most commonly in 
middle-aged and elderly patients, with peak during the sixth and seventh 
decades. Nonetheless, they also occur in children and the elderly. 
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Childhood examples tend to include more aggressive forms of 
meningioma.(3)   
• Etiology: Meningiomas are known to be induced by low-moderate and 
high-dose radiation with an average time interval to tumour appearance  
of 35, 26 and 19—24 year. The majority with radiation-induced 
meningiomas have a history of low-dose irradiation (800 rad) to the 
scalp for tinea capitis.(3) 
• Localization: The vast majority of meningiomas arise in intracranial, 
intraspinal or orbital locations. Intraventricular and epidural examples 
are uncommon. Within the cranial cavity, most meningiomas occur over 
the cerebral convexities, often parasagittal in association with the falx 
and venous sinus. Other common sites include the olfactory grooves, 
sphenoid ridges, para/suprasellar regions, optic nerve sheath, petrous 
ridges, tentorium and posterior fossa. Among other sites, metastases of 
malignant meningiomas most often involve lung, pleura, bone and 
liver.(3) 
• Clinical features: 
- Symptoms and signs: Meningiomas are generally slowly growing and 
produce neurological signs and symptoms by compression of adjacent 
structures. Headache and seizures often herald the presence of a 
meningioma.(3)  
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• Neuroimaging: On MRI, meningiomas are typically isodense, contrast-
enhancing dural masses. Calcification is best seen on CT scan. A 
characteristic feature of meningiomas is the so-called ‘dural tail’ 
surrounding the dural perimeter of the mass.(3) 
•  Histopathology: Meningothelial, fibrous and transitional meningiomas 
are the most common.(3) 
- Fibrous (fibroblastic) menmgioma: Uncommon in pure form, this 
meningioma variant consists of spindle cells forming parallel, 
storiform and interlacing bundles in a collagen-rich matrix.(3) 
- Transitional (mixed) meningioma: These common tumours feature 
the coexistence of meninothelial and fibrous patterns as well as 
transitions between these pattern.(3) 
-  Psammomatous meningioma: This designation is applied to 
meningiomas containing a predominance of psammoma bodies over 
that of the tumour cells which give rise to them.(3)  
-  Angiomatous meningioma: This meningioma variant feature, 
predominance of blood vessels over that of the tumour cells.(57)   
- Microcystic meningioma: This variant is characterized by cell with 
thin, elongate processes encompassing microcysts containing pale, 
eosinophilic mucinous fluid. 
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- Secretory meningioma: The hallmark of this tumour variant is the 
presence of focal epithelial differentiation in the form of intracellular 
lumina containing PAS-positive, eosinophilic secretion.(58)  
-  Metaplastic meningioma: A meningioma with striking focal or 
widespread mesenchymal components including osseous, 
cartilaginous, lipomatous, myxoid or xanthomatous tissue, singly or in 
combinations.(3) 
- Chordoid meningioma: A meningioma variant consisting 
predominantly of tissue histologically similar to chordoma, featuring 
cords or trabeculae of eosinophilic, often vacuolated cells in an 
abundant mucoid matrix background.(59)  
-  Clear cell meningioma: An often patternless meningioma composed 
of polygonal cells with clear, glycogen-rich cytoplasm and prominent 
blocky perivascular and interstitial collagen.(3) 
-  Atypical meningioma: A meningioma with increased mitotic activity 
or three or more of the following histologic features: increased 
cellularity, small cells with a high nuclear cytoplasmic ratio, 
prominent nucleoli, uninterrupted patternless or sheet-like growth, and 
foci of spontaneous or geographic necrosis. Increase mitotic activity, 
is defined as 4 or more mitoss per 10 high-power (40x) field (defined 
as 0.16 mm2).(60) 
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- Papillary meningioma: A rare meningioma variant defined the 
presence of a perivascular pseudopapillary pattern comprising the 
majority of the tumour. 
-  Rhabdoid meningioma: An uncommon tumour predominantly 
containing sheets of rhabdoid cells, i.e., plump cells with eccentric 
nuclei, often open chromatin, prominent nucleolus, and prominent 
inclusion-like eosinophilic cytoplasm appearing either as discernible 
whorled fibrils compact and waxy.(61)  
-  Anaplastic (malignant) meningioma: A meningioma exhibiting 
histological features of frank malignancy far in excess of the 
abnormalities present in atypical meningioma.(3)    
- Immunohistochemistry: The vast majority of meningiomas stain for 
epithelial membrane antigen. (EMA). Vimentin positivity is found in 
all meningiomas. 
Mesenchymal, non-meningothelial tumours: 
• Definition: Benign and malignant mesenchymal tumours originating in 
the CNS and histologically corresponding to tumours of soft tissue or 
bone.(3) 
• Grading: According to their histolkogical features and clinical 
behaviour, they range from benign neoplasms (WHO grade I) to highly 
malignant sarcomas (WHO grade IV).(3)  
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Tumours of adipose tissue: 
• Lipoma: This benign lesion microscopically resembles normal adipose 
tissue.(3) 
• Angiolipoma: The proportion of adipose cells and vasculature varies in 
this lipoma variant.(3) 
• Hibernoma: This lipoma variant is rare in the CNS. It resembles brown 
fat and composed of uniform granular or multivacuolated cells with 
small, centrally placed nuclei.(3) 
Fibrous tumours:  
• Fibromatosis: This locally infiltrative but cytologicaly benign.(62) 
• Solitary fibrous tumour: This lesion affects both cranial and spinal 
meninges. Its spindle cells are disposed in fascicles between prominent, 
eosinophilic bands of collagen.(3)  
• Fibrosarcoma: This rare, malignant tumour shows interlacing bundles 
of spindle cells disposed in “herringbone” pattern.(3) 
Fibrohistiocytic tumours:  
• Benign fibrous histocytoma: This lesion is composed of a mixture of 
spindled (fibroblast-like) and plump (histiocyte-like) cells arranged in a 
storiform pattern.(3)   
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•  Malignant fibrous histiocytoma (MFH): This neoplasm consists of 
spindled, plump and pleomorphic giant cells that can be arranged in a 
storilorm or fascicular pattern.(3)   
Myogenic tumours: 
•  Leiomyoma: Most benign smooth muscle tumours are readily 
recognized by their pattern of intersecting fascicles composed of 
eosinophilic spindle cells with blunt-ended nuclei.(3) 
•  Lelomyosarcoma: Intracranial leiomyosarcomas correspond 
histologically to their soft-tissue counterparts.(3)   
•  Rhabdomyoma: This lesion consists entirely of mature striated 
muscle.(3) 
•  Rhabdomyosarcoma: Whether meningeal or parenchymal, nearly all 
CNS rhabdomyosarcomas are of the embryonal type.(3) 
• Osteocartilaginous tumours: These benign osteocartilaginous tumours 
are usually dural-based; outside the CNS, they often develop in the skull 
and only secondarily displace dura and brain. Histologically, they 
correspond to similar tumours arising in bone, but are to be separated 
from asymptomatic dural calcification, ossification related to metabolic 
disease or trauma.(3) 
•  Mesenchymal chondrosarcoma: This neoplasm more often arises in 
bones of the skull or spine than within dura or brain parenchyma.(3) 
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•  Osteosarcoma: Preferred sites are the skull or spine and, more rarely, 
the meninges or the brain.(3) 
•  Vascular tumours: Most vascular lesions of the central nervous system 
are malformative in nature and include arteriovenous malformation, 
cavernous angioma, venous angioma and capillary teleangiectasis.(3)  
•  Haemangioma: These lesions vary in size from microscopic to 
massive.(3)  
•   Epithelioid haemangioendothelioma: Skull base, dura or brain are 
rare locations for this neoplasm.(3) 
•  Angiosarcoma: The rare examples originating in brain or meninges.(3) 
• Kaposi sarcoma: This malignant neoplasm is characterized by spindle-
shaped cells lining or forming slit-like blood vessels and is only 
exceptionally encountered as a parenchymal or meningeal tumour in the 
setting of AIDS.(3) 
Haemangiopericytoma:  
• Definition: A highly cellular and vascularized mesenchymal tumour 
exhibiting a characteristic monotonous low-power appearance and a 
well-developed, variably thick-walled, branching “staghorn” 
vasculature; almost always attached to the dura and having a high 
tendency to recur and to metastasize outside the CNS.(3)  
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•  ICD-O codes: Haemangiopericytoma 9150/1. Anaplastic haemangi- 
opericytoma 9150/3.(3) 
• Grading: Haemangiopericytomas correspond histologically to WHO 
grade II, with anaplastic haemangiopericytomas corresponding to WHO 
grade Ill.(3)  
•  Localization: Primary haemangiopericytomas of the CNS are almost 
invariably solitary and attached to the cranial or spinal dura.(3)  
•   Clinical features: As suggested by their location, the symptoms of 
meningeal haemangiopericytoma are indistinguishable from those of 
meningioma.(3) 
• Neuroimaging: On plain films, a well-demarcated, lytic-lesion of 
adjacent bone supports haemangiopericytoma, whereas hyperostosis, a 
typical feature of meningioma is absent.(3)   
•  Macroscopy: At surgery, meningeal haemangiopericytoma is a solid, 
well-demarcated tumour. It has a tendency to bleed during removal, 
sometimes profusely.(3)   
•  Histopathology: Haemangiopericytomas are monomorphous tumours 
tumours composed of closely peaked, randomly oriented tumour cells 
with little intervening fibrosis. Cytoplasm is scant and cell borders are 
indistinct. Nuclei are round to oval, occasionally elongated, with 
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moderately dense chromatin and inconspicuous nucleoli, lacking the 
pseudo-inclusions characteristic of meningiomas.(3) 
•  Immunohistochemistry: Haemangiopericytoma cells are diffusely 
immunoreactive for vimentin ‘(85%), factor Xllla (80-100%) in 
individual scattered cells.(3) 
Melanocytic lesions: 
•  Definition: Primary melanocytic neoplasms of the CNS that arise 
leptomeningeal melanocytes and that can be diffuse or circumscribed, 
benign or malignant. This group includes (1) diffuse melanocytosis and 
melanomatosis, (2) melanocytoma and (3) malignant melanoma.(3) 
•  Incidence: Melanocytoma account for 0.06 – 0.1% of brain tumours.(3) 
• Neuroimaging: CT and MRI of melanocytosis and melanomatosis 
shows diffuse thickening and enhancement of the leptomeninges, often 
with focal nodularity.(3)  
• Histopathology: Diagnosis hinges on the recognition of tumour cells 
that have melanocytic differentiation. Most benign and malignant 
melanocytic lesions display melanin pigment finely distributed within 
tumour cells and coarsely distributed within the tumour stroma and the 
cytoplasm of tumoural macrophages (melanophages).(3) 
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Germ cell tumours: 
CNS germ cell tumours: 
• Definition: Morphological and immunophenotypic homologues of 
gonadal and other extraneuraxial germ cell tumours.  
• ICD-O codes:(3) 
- Germinoma (9064/3).                   - Teratoma (9080/1).    
-  Mature teratoma (9080/0).           - Immature teratoma (9080/3) 
- Teratoma with malignant transformation (9084/3). 
- Yolk sac tumour (9070/3).          - Embryonal carcinoma (9070/3) 
-  Choriocarcinoma (9100/3) 
• Incidence: Geographic incidence varies considerably. Most prevalent in 
far-east Asia, CNS germ cell tumours accounted for 2-3% of primary 
intracranial neoplasms, and for 8-15% of specifically paediatric.(3) 
•  Age and sex distribution: Approximately 80-90% of CNS germ cell 
tumours afflict subjects younger than 25 years of age.(3) 
•   Localization: CNS variants preferentially affect the midline: 80% or 
more arise in structures about the third ventricle.   
• Neuroimaging: The neuroradiological profiles of CNS germ cell 
tumours are largely non-specific and definitive histological 
subclassification requires tissue examination.(3) 
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• Germinoma: The pure germinoma, the most common CNS germ cell 
tumour, is populated by large cells that appear un differentiated and that 
resemble primordial germinal elements (of which, in theory, they 
represent the neoplastic counterparts).(3) 
• Teratoma: Teratomas differentiate along ectodermal, endodermal and 
mesodermal lines (e.g. they recapitulate somatic development from the 
three embryonic germ layers). Mature and immature variants require 
distinvtion.(3) 
•  Mature teratoma: Mature teratomas are composed exclusively of fully 
differentiated, adult-type tissue elements. Mitotic activity is low or 
absent. The more common ectodermal components encountered in such 
tumours include skin, brain and choroid plexus. Mesodermal 
representatives include cartilage, bone, fat and muscle (both striated). 
Cysts lined by epithelial of respiratory or enteric type are the useful 
endodermal participants, with some examples also containing pancreatic 
or hepatic tissue. Not infrequently, gut-like structures are formed, 
replete with mucosa and muscular coats.(3)  
• Immature teratoma: This teratoma variant contains incompletely 
differentiated components resembling foetal tissues. Such incompletely 
differentiated areas mandate classification of the lesion as an immature 
teratoma even if they constitute only minor elements in an otherwise 
differentiated tumour, Particularly common are a hypercellular and 
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mitotically active “stroma” reminiscent of embryonic mesenchyme and 
primitive neuroectodermal elements that may fashion neuroepithelial 
rosettes and canalicular arrays mimicking the developing neural tube.(3) 
•  Teratoma with malignant transformation: These are generic 
designations for the occasional teratomatous neoplasm that contains as 
an additional malignant component a cancer of conventional somatic 
type.(3)  
• Yolk sac tumour: This neoplasm is composed of primitive- appearing 
epithelial cells-putatively representing yolk sac endoderm-set in a loose, 
variably cellular and often conspicuously myxoid matrix resembling 
extra-embryonic mesoblast.(3)  
•  Embryonal carcinoma: The embryonal carcinoma is composed of 
large cells that proliferate in cohesive nests and sheets, form abortive 
papillae of line irregular, gland-like spaces.(3) 
• Choriocarcinoma: The choriocarcinoma is characterized by extra-
embryonic differentiation along trophoblastic lines. The diagnosis 
requires the identitication of cytotrophoblastic elements as well as 
syncytiotrophoblastic giant cell.(3) 
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Tumours of sellar region:  
Craniopharyngioma:  
• Definition: A benign, partly cystic epithelial tumour of the sellar region 
presumably derived from Rathke pouch epithelium.  
•  ICD-O codes: 
- Craniopharyngioma (9350/1)   
- Adamantinomatous craniopharyngioma (9351/1). 
-  Papillary craniopharyngioma  (9352/1). 
• Grading: Craniopharyngiomas correspond histologically to WHO grade I.  
•  Incidence: Craniopharyngiomas account for 1.2-4.6% of all 
intracranial tumours, corresponding to 0.5-2.5 new cases per million 
population per year, being more frequent in Nigerian (18% of all CNS 
tumours).(3) 
•  Localization: The most common site is suprasellar with a minor 
intrasellar component. Unusual locations such as sphenoid sinus have 
been reported.(3) 
•   Clinical features: 
- Symptoms and signs: Clinical features are non-specific and essentially 
include visual disturbances (observed in 62-84% of the patients, more 
frequently in adults than in children) and endocrine deficiencies 
(observed in 52-87% of patients, more frequently in children).(3) 
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• Neuroimaging: for adamantinomatous craniopharyngioma, radiography 
provides an accurate depiction of the configuration of the sella and the 
typical calcifications CTs show contrast enhancement of the solid 
portions and the cyst capsule, as well as the typical calcifications.(3) 
• Macroscopy: Typically a lobulated solid mass, on closer inspection, 
adamantinomatous craniopharyngiomas often demonstrate a spongy 
quality as a result of a variable cystic component.(3)  
• Histopathology: Adamantinomatous craniopharyngioma is recognized 
by the presence of squamous epithelium disposed in cords, lobules and 
irregular trabeculae bordered by palisaded columnar epithelium. These 
islands of densely packed cells merge with loosely cohesive aggregates 
of squamous cells known as stellate reliculum. Nodules of “wet keratin” 
representing remnants of pale nuclei embedded within an eosinophilic 
keratinous mass are found in either the compact or looser areas. Cystic 
cavities containing squamous debris are lined by flattened epithelium. 
Granulomatous inflammation associated with cholesterol clefts and 
giant cells may be seen, but this is more typical of the 
xanthogranuloma.(3)  
Granular cell tumour of the neurohypophysis:  
• Definition: An intrasellar and/or suprasellar mass arising from the 
neurohypophysisor infundibulum, composed of nests of large cells with 
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granular, eosinophilic cytoplasm due to abundant intracytopiasmic 
lysosomes.(3) 
• ICD-O code: 9582/0.  
• Grading: Granular cell tumours correspond to WHO grade I.  
• Localization: GCTs arise along the anatomic distribution of the 
neurohypophysis, including the posterior pituitary and pituitary 
stalk/infundibulum.(3) 
• Clinical features: 
Symptoms and signs: The most common presenting symptom is visual 
field deficit secondary to compression of the optic chiasm.(3) 
• Neuroimaging: MRI typically shows a well-circumscribed suprasellar 
mass that most frequently displays homogeneous or heterogeneous 
contrast enhancement. 
• Histopathology: GCTs consist of densely packed polygonal cells with 
abundant granular eosinophilic cytoplasm. The architecture is typically 
nodular.  
• Immunohistochemistry: GCTs are variably positive for CD68(KP1)S-100.  
Metastatic tumours of the CNS:  
• Definition: Tumours that originate outside the CNS and spread 
secondarily to the CNS via the haematogenous route (metastasis) or by 
direct invasion from adjacent tissues.(3)  
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OBJECTIVES 
General objective: 
To determine the histopathological pattern of brain tumors among 
Sudanese patients operated in Alshaab Teaching Hospital from January 
1st 2009 to 1st April 2010. 
Specific Objectives: 
1. To determine the prevalence of brain tumors among Sudanese 
patients diagnosed and operated at Alshhaab Teaching Hospital . 
2.To determine the age, sex, residence in the mentioned group. 
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2. METHODOLOGY  
2.1. Study Design: 
This is descriptive retrospective study. 
2.2. Study period: From 1/1/2009 to 1/4/2010. 
2.3. Study field: 
The study was carried out at the National Health Laboratory and 
Alzhrawi Laboratory (Khartoum). 
The National Health Laboratory (NHL) is a National reference 
laboratory located in the center of Khartoum; it has several pathologic 
departments including a Histopathology Department and Cancer 
Research Center of Sudan. NHL is guided by a professional cadre and 
receives samples from different parts of Sudan.  
Alzhrawi Laboratory (private lab). 
2.4. Study Population: 
All cases of brain tumours that presented to NHL and Alzhrawi 
Laboratory in the period of the study. 
2.4.1. Inclusion criteria: 
All cases of brain tumours that were diagnosed histopathologically 
at the two mentioned centers .  
2.4.2. Exclusion Criteria: 
• Brain tumours cases that had no histopathological slides in the 
histopathology laboratory mentioned centers. 
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• Any case with inadequate information.  
• Poorly stained slides. 
2.5. Sampling technique:                                        
2.5.1. Ethical consideration:  
Consent was taken from the General Directors of National Health 
Laboratory and Alzahrawi Laboratory. 
2.5.2. Data collection: 
Data were collected from patient’s request forms in a pre designed 
questionnaire (appendix). All the histopathological slides of the study 
were retrieved and reviewed with the help and supervision of experienced 
histopathologists to confirm the brain neoplasm diagnosis, determine the 
histopathological types of the tumors and classify the tumor using WHO 
grading system.Eighty cases from Alzahrawi and (10) cases from 
National Health Lab. 
2.6. Data processing and analysis: 
The data were electronically processed and analyzed by computer 
using Statistical Package for Social Sciences (SPSS) software. The 
obtained results presented in tables and figure. 
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RESULTS 
The number of patients included in the study was 90 patients, who 
are diagnosed as brain tumour in 14 months period from January 2009 to 
April 2010. 
Characteristics of the study population are as follows: 
Age distribution: 
The minimum age affected by brain tumours was 2 year, and the 
maximum was 80 years with a mean age group affected by brain tumours 
was 45 to <60 years showing the highest percentage of brain tumors 28 
cases  (30.9%) followed by the age 10 <20  10 years 16 cases (16.7%) 
and then the age 30 to <49 years 17 cases (18.8%). (Table No. 3). 
Gender distribution: 
Male patients constituted (58.8%) 53 cases compared to female 
(41.1%) 37 cases. With    male to female ratio 1.43 : 1. 
Distribution of patients according to residence: 
Patients coming from centre of Sudan are 57 patients (63.3%), 6 
patients (6.6%) from north Sudan, 3 patients (3.3%) from south Sudan 
and 3 patients from East Sudan (3.3%) (Figure 2). 
Distribution of patients according to diagnosis: meningioma 
constituted 48 cases (53.3%), this was followed by a strocytoma 16 cases 
(17.7%), pituitary a denoma 8 cases (8.8%), craniopharyngioma 6 cases 
(6.6%), ependymoma 4 cases (4.4%), oligodendroglioma 3 cases (3.3%), 
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medulloblastoma 3 cases (3.3%), epidermoid cyst 1 case (1.1%) and 
undiagnosed 1 case (1.1%). (Table No. 1). 
Clinical Presentation: 
Headache was the commonest presenting syptom in 61,1% of 
patients, this is followed by convulsions (40%), blurring of vision 
(15.5%), loss of smell (11.1%), change of mood (10%), milky breast 
secretion (6.6%), unsteady gait (5.5%). (Table No. 4). 
Duration of the illness: 
The duration of syptoms, until the patients sought medical advice, 
ranged from 1 month to greater than 2 years. Four to seven months 
duration is the most frequent time interval taken by the patient, 
accounting (28%) of patients (Figure No. 3).   
WHO staging of patients: 
The study showed that the percentage of WHO grade I among  the 
tumours patients was (74.4%), WHO grade II (11.1%), WHO grade III 
(4.4%) and WHO grade IV (7.7%) (Figure No. 1). 
 Histological sub-types of meningioma: 
The most common sub-type of meningioma was mixed type (41%), 
this followed by meningothelial (35.4%). 
Atypical (8.3%), fibrous (6.3%) psamommatous (4.2%) and 
anaplastic (4.2%). (Table No. 7).  
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Histological sub type of astrocytoma: 
The most frequent sub type of astrocytoma was pilocytic 
astrocytoma (62.1%) followed by glioblastoma (31.2%) and fibrillary 
astrocytoma (6.2%) (Table No. (8). 
Distribution of brain tumors according to Radiological finding: 
• Ninety five percent of meingioma in MRI was solid, while (5%) showed 
cystic degeneration. 
• Astroctyoma (55.8%) was solid, while (44.2%) cystic. 
• Caniopharyngioma: all the cases were solid. (Table No. 6). 
Refere to table No. (9) Location of brain tumour: 
 We find that meningioma commonly in the parietal labes; this is 
followed by frontal, temporal, occipital. 
Supra sellar, olfactory groove, orbital and then cerebellum. 
Astrocytoma commonly in the parietal lobes followed by cerebellum, 
temporal lobes and suprasellar.Ependyrmoma in the frontal lobe. 
Oligodendroglioma in the temporal then frontal and occipital. Pituitary 
ademoma, all the cases were supra sellar. Craniopharyngioma more 
supraseller followed by frontal lobes. 
Medullo blastoma, the commonest site is the frontal labes. 
Refer to table No. 5, 48 cases in the cerebrum of the brain, 30 cases 
in the left side and 18 cases in the right side. 
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Table No. (1)   Distribution of the patient who attended to NHL and 
Alzahrawi labs according to Diagnosis of brain tumour. 
 
   Frequency Percentage 
Meningioma  48 53.3% 
Astrocytoma 16 17.7% 
Ependymoma 4 4.4% 
Oligo dendroglioma 3 3.3% 
Pituitary adenoma  8 8.8% 
Craniopharyngioma 6 6.6% 
Medulloblastoma 3 3.3% 
Epidermoid cyst 1 1.1% 
Undiagnosed 1 1.1% 
Total  90 100% 
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Figure (1)   Distribution of the patient diagnosis who attended to NHL 
and Alzahrawi labs according to WHO Grading of brain tumours 
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Figure (2): Distribution of the patient of brain tumours who attended 
to NHL and Alzahrawi labs according to Gender with male to female 
rashio 1,43:1 
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Table No. (2)   Distribution of the patient of brain tumours who 
attended to NHL and Alzahrawi labs according to Residence 
  
Residence   Frequency Percentage 
North 6 6.6% 
West 21 23.3% 
East 3 3.3% 
South 3 3.3% 
Center 57 63.3% 
Total  90 100% 
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Table No. (3)   Distribution of the patient of brain tumours who 
attended to NHL and Alzahrawi labs according to Age Group 
  
  Frequency Percentage 
Less than 4 years 4 4.4% 
5-9 2 2.2% 
10-14 6 6.6% 
15-19 10 11.1% 
29-24 3 3.3% 
25-29 2 2.2% 
30-34 6 6.6% 
35-39 11 12.2% 
40-44 13 14.4% 
45-49 7 7.7% 
50-59 8 8.8% 
60-64 3 3.3% 
65-69 3 3.3% 
70-74 2 2.2% 
Higher than 75  1 1.1% 
Unavailable 2 2.2% 
Total  90 100% 
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Table No. (4)   Distribution of the patient of brain tumours who 
attended to NHL and Alzahrawi labs according to Clinical 
Presentation. 
 
  Clinical presentation  Frequency Percentage 
Headache 55 61.1% 
Convulsion  36 40% 
Blurring of vision  14 15.5% 
Loss of smell 10 11.1% 
Change of mood  9 10% 
Milky breast secretion 6 6.6% 
Hemiplegia 5 5.5% 
Unsteady gait 5 5.5% 
Growth Retardation 4 4.4% 
Dizziness 3 3.3% 
Others  7 7.7% 
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Table No. (5)   Others clinical presentation among patients of brain 
tumour in NHL and Alzahrawi Laboratory. 
 
 Clinical presentation   Frequency Percentage 
Decrease hearing  1 1.1% 
Difficulty in walking 1 1.1% 
Drowsiness 2 2.2% 
Fatiquability 1 1.1% 
Loss of vision  1 1.1% 
Slurred speech   1 1.1% 
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Figure (3)   Distribution of the patient of brain tumours who attended 
to NHL and Alzahrawi labs according to duration of the illness. 
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Figure (4)  Brain tumour anatomical site among the study population 
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Table No. (6)   Distribution of the brain tumour according to the side 
of cereberum of the brain. 
  
Left Right 
30 18 
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Table No. (7) Distribution of brain tumour acceording to consistency 
of the tumour being solid or cystic  . 
  
  Solid  Cystic  
Meningioma  45 3 
Astrocytoma 7 9 
Ependymoma 3 1 
Oligo dendroglioma 1 2 
Pituitary ademoma  8 1 
Crainiopharyngioma 5 - 
Medulloblastoma 3 1 
Epidermoidcyst - 1 
Undiagnosed 1 - 
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Table No (8)   Distribution of the meningioma according to the subtypes 
  
  Frequency Percentage 
Meningothelial 17 35.4% 
Fibrous 3 6.3% 
Mixed type 20 41.7% 
Psamommtous 2 4.3% 
Atypical 4 8.3% 
Anaplastic 2 4.2% 
Total  48 100% 
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Table No. (9)   Distribution of astrocytoma according to sub-types  
  Frequency Percentage 
Pilocytic astrocytoma  10 62.1% 
Fibrillary 1 6.2% 
Glioblastoma 5 31.2% 
Total  16 100% 
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Table No. (10):  Distribution of brain tumours patients according to 
site in different areas of the brain 
 
Diagnosis 
Parietal 
lobes 
Temporal Frontal Occipital Cerebellar 
Supra 
seller 
Olfactory 
groove 
Orbital 
mass 
Meningioma 13 5 9 5 3 5 5 3 
Astrocytoma 6 3 - 2 5 2     
Ependymoma     3           
Oligodendroglioma 1 1 1 1         
Pituitary adenoma                 
Cranio-pharyngioma   1 2     8     
Medulloblastoma       1   5     
Epidermoid cyst     1           
Undiagnosed     1           
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DISCUSSION 
 Brain tumours are common, the annual incidence rate appears to 
increase steadily with age. Literature review showed no previous 
histopathological studies concerning brain tumours were carried out in 
Sudan. So, this is the first histopathological study of general pattern of 
brain tumours in Sudan. 
It may not be the exact in incidence because many cases were 
diagnosed in private laboratories and other hospital laboratories that were 
not included in this study. The actual number of brain cancers is most 
probably higher, but since the two selected institutions are the main 
histropathology centers in Sudan that received brain tumours samples, we 
can considered these results are acceptable. In Sudan as in most 
developing countries, at present there is no reliable statistical information. 
The poor registration of medical data was one of the biggest obstacles for 
this study. It made the data interpretation and statistical analysis difficult. 
 The mean age at presentation in this study is 45 years, maximum 
was 80 years and the minimum age is 2 years. This correlates well with a 
WHO data.(3) Also in a study by Middle East Concerum Centre,(1) that 
brain tumours can occur at any age. 
Our study showed that there is association between the age and the 
diagnosis, that 19 (cases) out of (48) cases of meningioma is between the 
age of 40-49 with 1 case at the age of 5-9 years and 1 case higher than 75 
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years. Within the following age groups the most common primary brain 
tumours are: 
• In ages 0-4, medulloblastoma, pilocytic a strocytoma, 
craniopharyngioma, Ependymoma. 
• In ages 5-9, medulloblastoma. 
• In age 10-14, pilocytic astrocytoma followed by craniophryngioma 
and medullobastoma. 
• In age 15-19, pilocytic astrocytoma, followed by craniopharyngioma 
and glioblastoma. 
• In age 20 – 24, pilocytic strocytoma, 
• In age 25 – 29, meningioma followed by pituitary adenoma. 
• In age 30 – 34 meningioma. 
• In age 35 – 39 meningioma followed by pilocytic astrocytoma. 
• In age 40 – 49 meningioma. 
• In age 50 – 54 meningioma. 
• In age 55 – 59, pituitary adenoma followed by meningioma. 
This results are similar to the results reported by American Brain 
Tumour Association excepted of age of 15-19, the commonest brain 
tumour was pituitary adenoma and also in age of 20 – 34, pituitary 
adenoma.(5)  
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Also this results are consistent with the WHO data that 
meningioma common in adult while pilpcytic astrocytoma, 
medulloblastoma, and craniophryngioma in children.(3) 
Also M, William Schwartz said that astrocytoma constituted 75% 
of childhood CNS tumours followed by medulloblastoma 20%, 
ependymoma and craniopharyngioma.(70) 
Male to female ration in this study is 1.43 : 1 with a male 
predominant this correlate with MECC studies (1) and with study done in 
Alsabah-hospital in Kuwit.(73) So brain tumour is more common in male 
than female. 
Our study found that the most common brain tumour is 
meningioma (53.3%) this correlate with the Dr. Hussein Abu-Salih study 
which done in Alshaab Teaching Hospital over a 10 years period          
(1971-1981).(75) One hundred twenty three cases of brain tumour 
encountered in the study. Meningioma constituted (45.5%).(75) Also 
correlate with Dr. Arbab study which done in Alshaab Teaching Hospital 
in a period of May 2005 – December 2007. They found that meningioma 
was the most common brain tumour constituted 72% followed by 
astrocytoma 22%.(74) Also correlate with study done in Al-sabah Hospital, 
Kuwait between 1995 and 2009, they found that the most common brain 
tumour was meningioma (28%), this followed by pituitary adenoma 19%, 
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glioblastoma (15%), a strocytoma (13%.).(73) In childhood astrocytoma 
(35.34%) followed by medulloblastoma (22.56%).(73) 
But is not correlate with study done in Howard University and DC 
General Hospital, 1954 to 1973, they found that the most common brain 
tumour in black was metastatic tumour constituted 34%, this is followed 
by glioma 28%, meningioma 20%, pituitary a denoma 13,1%.(72) Also not 
correlate with (1) the MECC (Middle East Concerum Centre) and with 
Saint John/s Health Center(71) studies, they said that the most common 
brain tumour is glioma. So why we have high incidence of meningioma? 
This may need more studies about the causes of brain tumours and about 
the risk factors and molecular. 
The study showed that the percentage of WHO grade 1 among 
brain tumour was (74.4%). Grade 1 meningioma constituted (87.9%). 
With 4.1% grade IV 
This finding in correlate with the Saint John's Health Center 
studies.(71) 
Regarding meningiom's sub types, we found that the most common 
subtype of meningioma was mixed type (41%). This result is not 
consistent with the Dr. Muna's study in meningioma who said that the 
common sub type is meningothelial? Also not consistent with the WHO 
which stated that the most common is meningothelial menigioma.(3) 
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In our study we found that meningioma common in the cerebrum, 
this followed by supra sellar, olfactory groove, orbital, cerebellum. 
These results were consistent with WHO data.(3) Also astrocytoma 
commonly in the parietal lobes followed by cerebellum, this is correlate 
with the WHO, who stated that pilocytic astrocytoma is common in the 
cerebellum in the children,(3) ependymoma in the frontal lobe, this not go 
the literature because ependymoma is common in the ventricles. 
Regarding residence (63.3%) from the centre of Sudan.  (33.3%) 
from the East. So it constituted a high percentage from the total in our 
study, we don’t know the causes. It needs further studies. 
Regarding the risk factors, it is not a heritable condition, but 
associated with several familial syndromes, like neuro fibromatosis, with 
gliomas and meningioma. Tuberous sclerosis with gliomas and rarely 
ependymomas, li fraumani syndrome with astrocytoma.(70) But in Sudan 
there is no studies. 
Regarding the clinical presentation, the most common presenting 
syptom is headache followed by convulsion and blurring of vision as 
theses syptoms of increase intra   cranial pressure-ataxia was a syptom of 
cerebellum lesion, so our clinical presentations correlated with the final 
diagnosis. 
There are one case which was not diagnosed in spite of panel of 
immuno histochemistry that LCA negative and CD 117 positive.  
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CONCLUSION 
 
The study concluded that, meningioma was found to be the 
commonest brain tumour among the study population, followed by 
astrocytoma, then pituitary adenoma and craniopharyngioma. Also, it was 
found that, it was more frequent among males than females as well as it is 
more common in the center of Sudan followed by the West, then the 
North. The most presenting symptoms were headache and convulsions. 
Brain tumours were more common in the left than the right.. Benign 
tumours are more than the malignant.  
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RECOMMENDATIONS 
 
• The study recommended for further studies, considering coverage of 
wider population and studying the risk factors.   
• A full history of suspected patients should be obtained so as to explore 
all aspects of the disease. 
• Health providers should organize specialized strategic program from 
brain tumour, and it is preferred to produce good efforts in its fund 
raising. 
• Regarding patients, awareness should be raised for early detection of 
the disease. 
•  Good registrations of the clinical informations. 
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ﻢﻴﺣﺮﻟا ﻦﻤﺣﺮﻟا ﷲا ﻢﺴﺑ  
University of Khartoum 
The Graduate College 
Medical and Health Studies Board 
  
Questionnaire 
Pattern of brain tumours in Sudanese Patients 
 
Serial No: ...........................................................           
1. Gender:          1.1. Male              1.2. Female  
2. Age:  ...................................................................           
3. Residence:     2.1. Khartoum      2.2. Dar Four        2.3. Kordofan 
                               2.4. Algezira         2.5. Others ……………………..……………..    
4. Tribe:  ...........................................................           
5. Clinical presentation:   
            5.1. Headache              5.2. Convulsion         5.3. Blurring of vision 
            5.4. Change of mode   5.5. Dizziness             5.6. Unsteady gaits           
            5.5. Others ……………………..……………..    
6. Duration: ...........................................................           
7. Imaging  MRI: 
           7.1. Parietal space occupying lesion:     1. Left              2. Right  
                                                                               a. Solid            b. Cystic 
           7.2. Temporal:           1. Left              2. Right                  
                                                a. Solid            b. Cystic 
           7.3. Frontal:               1. Solid             2. Cystic  
            7.4. Occipital:           1. Solid             2. Cystic  
           7.5. Cerebellar:         1. Solid             2. Cystic  
            7.6. Supra sellar:     1. Solid             2. Cystic  
             7.7. Others ……………………………………………..……………..    
 2
8. Diagnosis: 
           8.1. Meningioma                              8.2.  Pilocytic astrocytoma  
           8.3. Ependymoma                            8.4. Glioblastoma multiforme                  
           8.4. Oligodendroglioma                   8.5. Pituitary adenoma 
            8.6. Crianio pharyngioma               8.7. Medulloblastoma  
            8.8. Metastasis                                   8.9. Others:…………………………………… 
9.  WHO grading: 
          9.1. I               9.2.  II             9.3. III                   9.4. IV 
10.   Immuno-histochemistry:    10.1 Yes               10.2 No 
          If “Yes” Specify: ………………………………………………………………………………….. 
11.   Recurrent:       11.1 Yes               11.2 No 
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